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Interleukin-15 (IL-15) is a factor that promotes activation, proliferation, cytotoxicity, and
survival of CD8 T cells and NK cells, and has been shown to have anti-tumor effects.
Moreover, loss of IL-15 expression in human colorectal tumors correlates with increased
risk of relapse, diminished survival, decreased density and proliferation of T cells. All
together these findings suggest that IL-15 expressed locally in the tumor
microenvironment (TME) is an important mediator of anti-tumor responses by tumor
infiltrating lymphocytes (TILs) representing a potentially powerful immunotherapeutic
target. Unfortunately, the regulation and roles of IL-15 within the TME is unclear.
I hypothesized that IL-15 produced in the TME is an important factor promoting antitumor responses by cytotoxic lymphocytes stimulating their optimal numbers, enhancing
their effector functions and metabolic fitness. In this dissertation I investigated the cellular
sources and regulation of IL-15 in the TME and its roles in enhancing anti-tumor
immunity. I showed, using several murine tumor models, that soluble IL -15/IL15R complexes (sIL-15 complexes) are present at high levels in the interstitial
fluid of early tumors and decrease with tumor growth. Depletion of local IL -15 in
tumors led to decreased numbers of TILs without directly affecting tumor growth,
likely by promoting their infiltration into tumors. I also found that levels of sIL-15
complexes could be upregulated in advanced tumors by local activation of the Stimulator
v

of Interferon Genes (STING) pathway. While treatment of tumors with STING
agonists induces tumor regression, optimal STING-mediated systemic antitumor immunity required IL-15 expression. In addition, I examined the direct effect
of IL-15 agonists in poorly T-cell infiltrated tumors and found that recombinant sIL-15/IL15R-Fc complexes (rsIL-15c) and a polymer-conjugated IL-15R agonist significantly
slowed tumor growth and increased the total numbers of TILs. Moreover, intratumoral IL15 agonists in combination with anti-CTLA-4 immune checkpoint blockade synergistically
induced better tumor growth control and enhanced mouse survival in a poorly infiltrated
melanoma tumor model. These findings reveal the ability of IL-15 expressed within
the TME to regulate TIL numbers and upon upregulation by inflammatory
signals, contribute to enhanced anti-tumor responses.
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CHAPTER I: INTRODUCTION
CD8 T cells and natural killer (NK) cells are key mediators of anti-tumor immune
responses due to their ability to kill tumor cells with their cytotoxic properties. CD8 T
cells are adaptive lymphocytes that become activated when their T cell receptor (TCR)
recognizes its cognate antigen bound to a major histocompatibility complex I (MHC-I)
molecule on the cell surface of an antigen-presenting cell (APC). Conversely, NK cells
are innate lymphocytes whose activation is not limited by antigen recognition and
presentation by an MCH molecule. Instead their activation is tightly regulated by the
balanced interactions of inhibitory and activating receptors on the cell surface of NK
cells with MHC-I molecules on target cells. Understanding how to enhance the
responses and functions of these cytotoxic lymphocytes is important to ensure that
robust anti-tumor immune responses are achieved. Interleukin-15 (IL-15), a cytokine
that preferentially stimulates CD8 T cells and NK cells, will be the focus of this
dissertation. In recent years it has garnered attention as a potential immunotherapeutic
cytokine, but very little was known of its endogenous expression and roles as an
inflammatory protein in tumors. This dissertation will concentrate on uncovering its
roles and effects on anti-tumor responses when it is expressed in the tumor
microenvironment (TME). In the following chapter I will provide an overview of how the
TME impacts responses of cytotoxic lymphocytes, highlighting mechanisms of
immunosuppression. I will also elaborate on the role of type I interferons (IFN-I) in antitumor immunity and I will discuss known functions of IL-15 as a promoter of CD8 T
cells and NK cells responses and known mechanisms of regulation by other
inflammatory signals.
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1.1 Tumor microenvironment
Cancer as we understand it today is a group of diseases that is characterized by
abnormal and uncontrolled cellular growth that has the potential to invade surrounding
tissues and spread throughout the body. The first description of cancer was first
reported back in 3000 BC in ancient Egypt in the Edwin Smith Papyrus, where masses
of the breast tissue were surgically removed (1, 2). The Greek physicians Hippocrates
and Galen and the Roman physician Celsus are credited with being the firsts to refer to
ulcer-forming tumors are carcinomas, using the word oncos to describe tumors, and
translating the Greek word carcinoma to the Latin cancer, respectively (2). Regardless
of the origin of the word, cancers proved to be extremely difficult to treat and for many
years were thought incurable (1). However, as we have developed more advanced
investigative techniques and more targeted treatment options, we have a better
understanding of the key events that must take place for cancer development and the
characteristics that make certain cancers more difficult to treat and cure.
The development of cancer is a multi-step and multifactorial process that begins
with alterations to the genetic material of a single cell, that can include the activation of
cancer-promoting genes, or oncogenes, and/or the loss of function of tumor suppressor
genes, that initiate the process of cellular transformation and proliferation of this
mutated cell (3). Upon clonal expansion of this mutated cell, accumulation of more
mutations in this population of cells can confer selective advantages such as enhanced
growth capability to certain cells that become the dominant cell population. This
process termed clonal selection, occurs throughout tumor development generating a
heterogenous mass of tumor cells. As mutations continue to accumulate, these
transformed cells acquire malignant characteristics that make them more efficient at
2

evading the attempts of the body to control their unmitigated cellular proliferation and
invasion of surrounding tissues (4).
Our current understanding of how tumors develop and progress to invasive
masses that can metastasize throughout the body led to the identification of very
specific characteristics of tumors that were termed the hallmarks of cancer by Hanahan
and Weinberg (5, 6). In 2000 they proposed six main hallmarks of cancer that included:
self-sufficiency of growth signals, evading growth suppressors, evading apoptosis,
limitless replicative potential, sustained angiogenesis and tissue invasion and
metastasis (5). In their apt analysis of tumors they also pointed to potential
contributions by other cell types that form the tumor mass and that now we come to
appreciate are key components of the TME. In their 2011 revised hallmarks of cancer
they included genomic instability, deregulation of cellular energetics, tumor promoting
inflammation and avoiding immune destruction (6). Importantly, they demonstrated that
the cells that are part of the TME are key contributors to these important processes and
characteristics that promote the progression of tumor development and metastatic
potential. In this section I will provide an overview of how tumors are recognized by the
immune system, the cells that are part of the TME and their roles in either promoting or
impeding robust anti-tumor responses, and specific mechanisms of immune evasion.

1.1.1 Detection of tumors by the immune system
The immune system is designed to protect humans and animals from invading
pathogens by the detection of microbial and viral components. This feat is achieved
because many innate immune cells express on their cell surface and the cytoplasm a
variety of pattern recognition receptors (PRRs) that recognize pathogen associated
3

molecular patterns (PAMPs) from viruses and bacteria and distress signals from host
cells, known as danger associated molecular patterns (DAMPs) (7). APCs such as
dendritic cells (DCs) and macrophages can detect PAMPs and DAMPs that can directly
ligate PRRs on the cell surface of APCs or can be engulfed by these innate immune
cells and interact with cytoplasmic PRRs. The ligation of PRRs induces downstream
signaling pathways that promote anti-viral and anti-bacterial inflammatory processes
that aid in the destruction of the pathogen. Once APCs engulf these particles, they
process them inside the cells to present on the cell surface bound to MHC-I and MHC-II
molecules. APCs present antigens to cells of the adaptive arm of the immune system,
including CD8 and CD4 T cells, that become activated and exert their functions to
eliminate the foreign invaders.
Similarly, products of cell death including DNA, RNA and tumor-derived antigens
are also sensed by PRRs on APCs that trigger the production of cytokines, including
IFN-I and chemokines, and priming of T cells by presentation of tumor antigens (8-10).
Furthermore, cellular stress and damage can increase the expression of ligands on
tumor cells that bind activating receptors on NK cells and leads to tumor cell death. On
the other hand, mutations in the genome that occur during the transformation process,
induce the production of mutated proteins by cancer cells that are also presented on
the cell surface on MHC-I molecules (11) and can be recognized as foreign by adaptive
lymphocytes. These mutated proteins are known as neoantigens and are currently
being targeted for enhancing the efficacy of immunotherapies including adoptive cell
therapies and personalized cancer vaccines (12).
Consequently, although for many years it was thought that the immune system was
not capable of distinguishing between normal and malignant self-tissues, we now
4

understand that immunosurveillance by innate and adaptive immune cells is important
for protecting the host against not only foreign pathogens but also cancer and disease
development (13) . Nonetheless, despite the many ways in which the immune system
can effectively recognize cancer cells, tumors have developed several strategies to
undermine both the innate and adaptive immune responses and are aided in part by
the stromal cells that are part of the TME. In the next section I will describe the cells
that form part of the stromal component of the TME and the mechanisms of immune
evasion will be further discussed in section 1.3.3 of this chapter.

1.1.2 Composition of the tumor microenvironment
Tumors are masses composed of a heterogeneous population of transformed
cells and several other cell types that are part of the TME. The other cellular
components of the tumor mass include stromal cells like fibroblasts, vascular
endothelial cells, blood vessels, lymphatic vessels and immune cells. Other
components of the TME include inflammatory mediators and soluble factors such as
cytokines, chemokines, growth factors, extracellular matrix (ECM) proteins and
nutrients including oxygen, glucose, amino acids, fatty acids and their metabolites. In
the next few paragraphs I will describe and discuss the functions and roles of some of
these components in the TME.
The first cell type I will discuss are fibroblasts, which are the main generators of
ECM in connective tissues and produce transforming growth factor  (TGF-) during
tissue repair and wound healing (14). Fibroblasts that reside in secondary lymphoid
organs are known as fibroblastic reticular cells (FRCs) and in this context they produce
ECM that allows formation of lymphatic conduits for the transport of chemokines,
5

cytokines and antigens to present to T cells in lymphoid tissues (15). They also
produce several chemokines like C-C motif ligand 19 (CCL19) and CCL21, that upon
binding to C-C motif chemokine receptor 7 (CCR7) on DCs and naïve T cells promotes
the DC and T cell interactions for their activation (16). Other chemokines and cytokines
produced by FRCs include C-X-C motif ligand 13 (CXCL13) , CXCL12, IL-7 and B-cell
Activating Factor (BAFF) are important for recruitment of T cells, B cells, follicular
helper T cells and DCs to secondary lymphoid organs and for survival of T cells and B
cells (15). In the TME normal fibroblasts can become cancer associated fibroblasts
(CAFs) in response to several stimuli including direct contact with cancer cells and
induction of Notch signaling, in response to inflammatory proteins like IL-1 and IL-6 and
in response to physiological stress and DNA damage (17).
CAFs can promote tumor progression and suppress immune responses against
tumors by several mechanisms including deposition and remodeling of ECM to
increase metastatic spread of tumor cells, limiting CD8 T cell interaction with tumor
cells and increasing the stiffness of tumor tissues making it harder for immune cells to
infiltrate into tumors (18-20). They can also produce growth factors like TGF-,
leukemia inhibitory factor (LIF) and fibroblast growth factor 5 (FGF5) that can promote
proliferation and invasiveness in cancer cells (17, 21-23). CAFs can also promote
angiogenesis through the production of vascular endothelial growth factor (VEGF) (24).
They can also produce immunosuppressive cytokines and chemokines including IL-6
and CXCL12, that coats cancer cells and decreases TIL infiltration (25-27). Lastly, they
can cross-present antigens that induce specific deletion of CD8 T cells (28).
The next component of the TME that I will discuss are tumor endothelial cells
(TECs) and blood vessels. TECs line the inside of the blood vessels and in tumors are
6

involved in the process of angiogenesis. Angiogenesis is the formation of new blood
vessels in tumors to supply oxygen and nutrients to sustain tumor cell growth (29). In
response to hypoxia, an angiogenic switch is undergone in tumor cells that produce
angiogenic factors, like VEGF-A, that interacts with VEGF receptor-2 (VEGFR-2) on
nearby TECs initiating the formation of new blood vessels (29, 30). In this setting TECs
use matrix metalloproteinases to remodel and breakdown the ECM allowing the
migration of TECs to form new tumor blood vessels (31). The blood vessels in tumors
present an immature structure that leads to irregularly shaped vessel networks that do
not maintain their typical organization (32). These blood vessels have fewer smooth
muscle cells and pericytes, which allow the transendothelial migration and
dissemination of tumor cells to the circulation. TECs can also express Programmed
Death-1 (PD-1) ligands 1 (PD-L1) and PD-L2, ligands for the PD-1 inhibitory receptor,
that can further inhibit T cell responses in tumors (33). Moreover, while normal
endothelial cells express cell adhesion molecules like ICAM-1, in contrast TECs
downregulate expression of these adhesion molecules in response to VEGF-A limiting
T cell extravasation into tumors (30, 34).
Lymphatic vessels are also important components of the TME that aid in the spread
and dissemination of tumor cells to other parts of the body, however they are also
essential for mounting anti-tumor immune responses. Lymphatic vessels in and around
tumors can expand and generate new vessels in response to VEGF-C, produced by
macrophages and tumor cells in a process termed lymphangiogenesis (35-37).
Lymphatic vessels surrounding tumors can expand and enlarge in response to VEGF-C
and this increased surface area can provide more contact space between lymphatic
vessels and tumor cells to allow for their entry into the lymph and metastatic spread to
7

nearby lymph nodes (38, 39). Moreover, lymphatic endothelial cells (LECs) can also
cause immune suppression of T cell responses by crosspresenting antigens on MHC-I
molecules in the absence of costimulatory signals leading to anergy of antigen specific
T cells (40). LECs in tumors can upregulate expression of PD-L1 leading to
engagement with PD-1 on T cells that can contribute to their tolerization and
dysfunction (41). LECs can also suppress T cell responses by their expression of
indoleamine 2,3 deoxygenase (IDO) that leads to tryptophan depletion, a necessary
amino acid for T cell proliferation and functions (42-44). However, lymphatics also play
important roles in promoting anti-tumor responses. Lymphatic vessels can carry tumor
antigens to lymph nodes where APCs can process them and present them to T cells to
induce the activation of these cells (37). Interestingly, lymphangiogenesis and
expression of VEGF-C are associated with increased TILs numbers and better
responses to immunotherapies in melanoma (45). These findings are likely mediated
by the upregulated expression of chemokines like CCL21, that promote homing of DCs
to lymph nodes, in response to VEGF-C (45). The previously discussed cell types form
part of the structural component of the tumor stroma, in the next paragraphs I will
discuss the cells that compose the immune infiltrate in the TME.
In the TME we find a variety of myeloid cells that have both mature and immature
phenotypes and that can have both stimulatory and suppressive roles for anti-tumor
responses mediated by cytotoxic lymphocytes. The first subset of cells to be discussed
are the DCs, which are the classical example of professional APCs. In the TME,
immature dendritic cells can uptake and process tumor antigens, including products of
cellular death, that induce their maturation and their ability to present them on the cell
surface on MHC-I and MHC-II molecules. Mature DCs can home to tumor draining
8

lymph nodes where they interact with CD4 and CD8 T cells. The main function of DCs
is to activate T cells by providing several signals required for effective T cell activation.
Signal 1 is achieved by the presentation of antigen on MHC molecules on the surface
of DCs and the interaction with the TCR on the cell surface of T cells (46). The second
signal is achieved by the interaction of costimulatory molecules expressed on the cell
surface of DCs, such as CD80 or CD86, with the receptor CD28 on the cell surface of T
cells (46, 47) . Costimulation signals are necessary for T cell proliferation,
differentiation and even survival. Without costimulation T cells become anergic and
eventually die (48).
DC subsets in mice can be divided into two main types: plasmacytoid DCs (pDCs)
and conventional DCs (cDCs), which can be further classified into type 1 cDCs (cDC1)
and type 2 cDCs (cDC2) subsets (49). While cDC1s have been identified as key
promoters of CD8 T cell mediated anti-tumor immunity, the roles for the other two
subsets of DCs in the TME are not clearly defined. The cDC1 subset of DCs, which rely
on basic leucine zipper transcriptional factor ATF-like 3 (Batf3) transcription factor for
their development and express the integrin CD103 (50), are of particular importance in
anti-tumor responses. cDC1 DCs are also known as Batf3+ DCs. Several studies have
shown that IFN-I signaling in Batf3+ DCs is crucial for tumor growth control (9, 51).
Moreover, loss of cDC1 cells leads to failure of adoptive cell therapies and checkpoint
inhibitor therapies to reject immunogenic tumors (52-54). Importantly, Batf3+ DCs are
extremely efficient in cross-presentation of exogenous antigens to CD8 T cells and in
the TME they are required for spontaneous priming of CD8 T cells and loss of these
cells decreased the infiltration of endogenous and effector CD8 T cells into tumors (53-

9

55). Moreover, cDC1s in the TME produce chemokines CXCL9 and CXCL10 to recruit
effector CD8 T cells into tumors (54).
Regarding the roles of the other two subsets of DCs in anti-tumor immunity very
little is known. pDCs are known for their important roles in anti-viral immune responses
and they generate high levels of IFN-I upon activation of TLRs by binding to nucleic
acids (56). In the context of cancer, pDCs found in tumors are usually associated as
tumor-promoting immunosuppressive cells that, in breast and ovarian cancers, produce
low levels of IFN-I and can even promote Treg differentiation (56-58). Lastly cDC2 cells
are very adept at presenting antigens on MHCII molecules to CD4 T cells, and are
capable of uptake of tumor antigens and inducing T cell proliferation in vitro (52).
As DCs in the TME play crucial roles in stimulating anti-tumor immunity, the tumor
has developed mechanisms to suppress the functions of DCs. Several of these
mechanisms include the production of soluble factors that inhibit DC functions including
IL-6, IL-10, VEGF, TGF- (59). These factors suppress DC functions by inhibiting their
maturation, differentiation, migration and even turning DCs into tolerogenic DCs that
can induce T cell anergy (60). For example, IL-6, TGF- and IL-10 can inhibit DC
maturation and IL-10 can convert immature DCs into tolerogenic DCs (61-64).
Among the cells that compose the tumor stroma the tumor-associated macrophages
(TAMs) are one of several other myeloid cells types, that are particularly associated
with sponsoring tumor progression. Monocytes in the circulation migrate to the TME in
response to growth factors and once they reside there they differentiate into TAMs (65).
Two main types of TAMs can be identified based on their phenotype: M1, which have a
more inflammatory and protective phenotype and M2, which have a more
immunosuppressive phenotype. TAM differentiation into M1 or M2 phenotypes is
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mediated by exposure to cytokines and growth factors in the TME (66, 67). M2 TAMs
acquire immunosuppressive functions and can release many types of soluble factors
that promote tumor progression including VEGF, TGF-, IL-10, prostaglandin E2
(PGE2) (66-70). They can also produce arginase that depletes arginine from the TME
(71), which in turn leads to decreased expression of TCR  and decreased T cell
proliferation (72)
Other subsets of granulocytes found in the TME are tumor-associated neutrophils
(TANs) and their immature counterparts including monocytic and granulocytic myeloid
derived suppressor cells (MDSCs). TANs, similar to TAMs, are classified as antitumorigenic N1 neutrophils and pro-tumorigenic N2 neutrophils. N1 neutrophils can
induce TRAIL-mediated apoptosis of tumor cells, promote ECM degradation, produce
reactive oxygen species (ROS) for lysis of cancer cells and mediate antibody
dependent cell cytotoxicity (ADCC) of cancer cells (73). In contrast, N2 neutrophils in
the TME can promote tumor progression and growth by promoting angiogenesis
through production of VEGF and ECM remodeling by upregulation of matrix
metalloproteinases (74). They can also recruit regulatory T cells (Tregs) and produce
arginase to deplete arginine and suppress T cell function and proliferation (75-77). The
second granulocytic population to be discussed here are MDSCs. MDSCs are a
heterogenous population of immature myeloid cells that have similar characteristics to
granulocytes and monocytes (78). MDSCs can be activated in the TME by several
soluble factors including cytokines, chemokines and growth factors and they exert
immunosuppressive functions (79). In the TME, MDSCs can suppress protective
lymphocyte anti-tumor responses by upregulating enzymes such as arginase, NOS and
IDO that limit T cell and NK cell cytotoxic activities against tumor cells (78-81).
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A very important subset of cells found in the TME are tumor-infiltrating
lymphocytes, among which there are several types that have both pro- and anti-tumor
roles. The lymphocyte subsets that will be discussed in the next several paragraphs are
CD8 T cells, NK cells and CD4 T cells including Tregs. First, CD8 T cells are one of the
two subsets of lymphocytes that can directly mediate tumor cell killing and their
presence in tumors correlates with better prognosis and therapeutic responses (82-85).
To be able to travel into the tumor, naïve CD8 T cells must become activated effector
cells upon recognition of tumor antigens presented by DCs in tumor draining lymph
nodes. These cytotoxic effector cells then migrate to the tumor site via lymphatic
vessels and are guided by chemokine gradients, especially chemokines CCL5 and
CXCL9 produced by tumors cells and myeloid cells in the TME, respectively (86) .
Upon entry into the tumors they can recognize tumor cells via their TCR and mediate
tumor cell death by secretion of perforin and Granzyme B or through direct induction of
apoptosis via ligation of death receptors (87). Upon activation, cytotoxic CD8 T cells
upregulate the expression of inhibitory receptors including cytotoxic T lymphocyte
associated protein 4 (CTLA-4) and PD-1 which upon binding to their respective ligands
suppresses T cell function (46). Among these, the PD-1/PD-L1 inhibitory checkpoint
has been shown to be particularly important for inhibiting CD8 T cell responses in
tumors (88). Moreover, once in the TME CD8 T cell functions can also be suppressed
by anti-inflammatory and suppressive cytokines and metabolic barriers induced by
catabolic metabolism of nutrients essential for T cell functions and survival.
The second subset of cytotoxic lymphocytes found in tumors are NK cells. These
innate lymphocytes can also kill tumor cells using similar mechanisms as CD8 T cells
however, their function is not restricted by antigen presentation on MHCI molecules.
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Activation of NK cells is mediated by engagement of cell surface activating and
inhibitory receptors with ligands in normal and transformed cells. In the TME, tumor
cells can downregulate the cell surface ligands to the activating receptors on NK cells
and avoid their cytotoxic actions (89). While NK cells are generally thought as being
one of the key mediators of anti-tumor immunity, new evidence suggest that, while in
the TME, NK cells can undergo polarization and even transformation into MDSCs in
response to factors like VEGF and granulocyte-macrophage colony-stimulating factor
(GM-CSF) (90, 91).
The last subsets of immune cells in the TME to be discussed in this section are
CD4 T cells, which also include Tregs. CD4 T cells can be further subdivided into Th1,
Th2, Th9, Th17, Th22 and Tregs, but in in this dissertation I will only discuss the Th1,
Th17 and Treg subsets. Th1 cells are pro-inflammatory and secrete IL-2 and IFN- to
aid CD8 T cell responses. Th17 cells have been shown to play dual roles including
promoting tumor growth by releasing IL-17A or turning into Tregs and potentiating CD8
T cell functions by increasing their recruitment to the tumor (92, 93). Lastly, Tregs
differentiate from naïve CD4 T cells, in response to IL-10 and TGF- and high
numbers of these cells in tumors are associated with decreased patient survival (94).
They can also inhibit DC maturation by secreting TGF- and IL-10, and they can inhibit
T cell activation by depleting IL-2 by releasing soluble CD25 (95, 96).
In the TME, complex interactions between cancer cells and stromal cells can lead
to the eventual escape of tumor cells from the attack of adaptive immune cells (Fig. 1).
Several mechanisms of immune evasion have been established and they mostly rely
on evading immune recognition, hindering immune cell activation and survival, and
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impeding tumor-killing functions of cytotoxic lymphocytes. The specific mechanism that
suppress tumor immunity will be discussed in the following section.

Figure 1. Immune cells and tumors cooperate in the TME to suppress anti-tumor
immunity. In the TME, both tumor cells and suppressive stromal cells can produce
factors such as TGF-, IL-6, IL-10, PGE2 and ROS that can inhibit the functions and
proliferation of cytotoxic lymphocytes and Batf3+ DCs. Other enzymes like arginase
and IDO produced in the TME can deplete important amino acids for cytotoxic
lymphocyte function and metabolic activities. In support of tumor growth, endothelial
cells and cancer associated fibroblasts and even immune cells produce growth factors
and angiogenic factors that promote generation of new blood vessels, proliferation and
invasive potential of tumor cells.
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1.1.3 Mechanisms of immune evasion and suppression of anti-tumor immunity
To avoid and escape detection by innate and adaptive immune cells tumors have
developed several strategies that result in progression and eventual metastatic spread
of disease. For example, tumors downregulate MHC I molecules to avoid detection by
APCs and T cells that can recognize mutated tumor antigens on their cell surface (97).
What is more, downregulation of MHC I molecules correlates with worst clinical
outcomes in patients (97). Moreover, tumor cells and stromal cells in the TME secrete
soluble factors including IL-6, TGF- and VEGF that can inhibit DC maturation and
downregulation of costimulatory molecules necessary for the successful activation of
CD8 T cells against tumors (98-100). If T cells fail to receive adequate costimulatory
signals they become anergic or tolerogenic leading to their eventual demise (101).
Interestingly, when the immune cells initially recognize and eliminate malignant
cells that express mutated antigens this means that less immunogenic cancer cells
survive and these cells are, as a result of transformation, more adept at evading
detection by immune cells. This process is known as immunoediting and it eventually
leads to tumor progression (13, 102). Moreover, tumor cells can also decrease the
expression of ligands for activating receptors on the cell surface of NK cells, thus
avoiding recognition by these innate lymphocytes (103). Consequently, decreased
expression of MHC-I molecules, immunoediting and inhibition of lymphocyte activation,
by loss of costimulatory signals and ligands for activating receptors are a few of the
intrinsic mechanisms that allow cancer cells to avoid immune detection.
There are other physical and chemical barriers in the TME that prevent the
infiltration and activity of cytotoxic lymphocytes. Stromal cells including CAFs, TECs,
and MDSCs in the TME contribute to the exclusion of CD8 T cells from tumors. CAFs
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can remodel and deposit ECM to make tumor tissues more rigid and produce CXCL12,
that coats cancer cells, to limit CD8 T cell infiltration (19, 25). TECs can induce CD8 T
cell apoptosis due to their high expression of FasL (104). In addition, MDSCs can
produce reactive nitrogen species (RNS) that can nitrate important chemokines for CD8
T cell infiltration (105).
In the TME, infiltrating cytotoxic lymphocytes face a very metabolically-challenging
environment, especially as activated T cells rely on glucose metabolism, through
glycolysis, for their proliferation and effector functions (106). Cancer cells have a very
high rate of glucose uptake and glycolytic activity leads to production of high lactate
levels (107). This process occurs even when oxygen is present in the system and
tumor cells have normal mitochondria (108). Low levels of glucose in the TME can lead
to T cell anergy, decreased proliferation, decreased secretion of cytokines and reduced
anti-tumor activity (109, 110).
Cancer cells can also use amino acids and fatty acids to maintain their metabolic
needs and proliferate (111). MDSCs and other immunosuppressive cells in the TME
can produce arginase to deplete arginine, a critical amino acid for T cell effector
functions (112) and produce ROS and RNS that are toxic to CD8 T cells in tumors
(113). Furthermore, high levels of lactate in the TME are associated with decreased
IFN- production by cytotoxic lymphocytes in tumors (114). Lastly, tumor and stromal
cells in the TME produce IDO that depletes tryptophan and produces toxic metabolites
that can suppress the anti-tumor responses by CD8 T cell and NK cells (115-117).
The last mechanisms of immune suppression that I will discuss is the engagement
of inhibitory receptors on the cell surface of T cells that cause attenuation of their
functions (118). Regulation of immune responses by adaptive lymphocytes is
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necessary to ensure that autoimmunity is not developed. As part of the normal process
of immune activation, immune checkpoints are engaged to limit the responses of
lymphocytes and to ensure that once the threat has been eliminated no damage occurs
to the host. The most widely known and studied immune checkpoints are CTLA-4 and
PD-1. These were discovered between the 1980’s and 1990’s and identified as
mechanisms to attenuate T cell responses. T cells that have high expression of these
inhibitory receptors show decreased production of cytokines, like IFN- and show an
exhausted phenotype (119). These inhibitory receptors and their respective ligands are
expressed by T cells, tumor cells, and other immune cells in the TME.
The ligands for CTLA-4 are CD80 and CD86 and for PD-1 they are PD-L1 and PDL2 and they can be upregulated on tumor cells in consequence of constitutive
activation of oncogenic pathways (120). CTLA-4 mostly inhibits T cell activation by
disrupting TCR signaling and decreasing the accessibility to costimulation by engaging
with CD80/86 on the surface of APCs (121, 122). PD-1 inhibits T cell activity by
decreasing the expression of survival factors and decreasing cytokine production (121,
123). While CTLA-4 can affect CD8 T cell functions, it mostly modulates CD4 T cells
and, due to its important role in preventing autoimmunity it can also promote
immunosuppressive functions of Tregs (124). Engagement of inhibitory immune
checkpoints causes inhibition of T cell and NK cell effector functions and promotes
Tregs activity. Thus, activation of these inhibitory receptors is another mechanism that
tumors use to suppress the immune response and currently therapies targeting these
immune checkpoints, also known as immune checkpoint blockade, are being widely
developed and studied for the treatment of many solid tumors and other malignancies.
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The TME with its immunosuppressive actions in combination with intrinsic
mechanisms of immune evasion by tumor cells prove that, although these mechanisms
may seem redundant, as many cell types produce very similar tumor-promoting growth
factors and cytokines, they are necessary for cancers to ensure their survival. This also
underscores how capable these malignant cells are to adapt to the arsenal of antitumor actions of the immune system. Accordingly, we must ensure to consider these
evasion mechanisms when designing new therapies or finding ways to improve current
ones. However, as the mechanisms that tumors co-opt to ensure their continued
development become better understood, new therapeutic interventions have been
developed to alter the TME to become more permissive of immune cell functions.
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1.2 Type I Interferons in cancer therapy
Interferons (IFN) were discovered in 1957 and received their name because
they interfere with viral replication and mediate viral interference, a phenomenon in
which a virus-infected cell becomes resistant to a secondary infection by another virus
(125). Three classes of IFNs have been identified including: type I IFN (IFN-I), type II
IFN (IFN-II), and type III IFN (IFN-III). The IFN-I family of cytokines is encoded by
multiple genes that produce several IFN- proteins (13 in humans and 14 in mice), one
IFN- and other less studied IFNs including IFN-, IFN-, IFN-, IFN-, IFN- and IFN (125). IFN- is the only member of the IFN-II family and its roles as an effector
molecule, produced primarily by activated lymphocytes and to a lesser extent by APCs,
are well documented (126). The IFN-III family is composed of four homologous proteins
IFN- 1-4 (127). Regardless of the type of IFN they promote anti-viral responses by
both innate and adaptive immune cells. In this section, I will highlight the important
functions of endogenous IFN-I during anti-tumor responses.

1.2.1 IFN-I signaling
IFN-I are produced by virtually all cell types upon stimulation of receptors known
as PRRs. During infection with pathogens or in situations of cellular death, PRRs
recognize microbial products, known as PAMPs, products of necrotic cell death, known
as alarmins or DAMPS and cytosolic nucleic acids (7). Several types of cell surface and
cytosolic PRRs are associated with IFN-I production including Toll-like receptors
(TLRs), retinoic acid-inducible gene 1 (RIG-1), melanoma differentiation-associated
gene 5 (MDA-5) and NOD-containing protein-1 (NOD1) and NOD2 (128-131). Other
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cytosolic receptors, that recognize cytosolic DNA, including cytosolic G-AMP synthase
(cGAS) and Z-DNA-binding protein 1 (ZBP1), can also induce IFN-I production (132,
133). The multitude of PRRs that can induce IFN-I expression underscores the
importance of IFN-I expression during pathogenic infections and upon situations of
cellular damage or death.
Upon stimulation of PRRs several downstream signaling pathways converge on
the Interferon Regulatory Factor (IRF) family of transcription factors, particularly IRF3
and IRF7, which in turn upregulate the transcription of IFN-I genes. IFN-I induce
signaling through the dimeric IFN-/ receptor (IFNAR) which can be composed of two
IFNAR1 subunits or a heterodimer of IFNAR1 and IFNAR2 (134). Downstream
signaling of the IFNAR includes induction of the Janus activated kinase- signal
transducer and activation of transcription (JAK/STAT) pathway, phosphoinositide 3kinase (PI3K) pathway, mitogen-activated protein kinase (MAPK) pathway and the
canonical and non-canonical nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-B) signaling pathways (135-137). Successively, these various signaling
pathways upregulate the transcription of many IFN-stimulated genes (ISGs) whose
products including cytokines, chemokines and survival factors among others, are not
only important for intrinsic anti-viral mechanisms but can enhance the maturation and
functions of many immune cells such as DCs, macrophages, CD8 T cells and NK cells
(136). Thus, IFN-I are critical promoters of both innate and adaptive immune responses
against viruses. Likewise, due to their stimulatory effects on many immune cell types
they are now appreciated as important factors for intrinsic and therapeutic anti-tumor
responses.
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1.2.2 IFN-I roles in cancer immunoediting
For many years it was believed that our immune system was blind to
transformed cells because they are derived from self-tissues. It wasn’t until the 1970’s
and 1980’s, that the theory of cancer immunosurveillance, a process by which the
immune system protects the host against oncogenesis, was independently proposed by
Burnett and Thomas (138-140). However, it took several decades to prove that the
immune system can recognize malignant cells and eliminate them without overt or
external stimulation. This delay was due in part by the lack of adequate animal models
in which to test this theory. As proper animal models were developed, including
Recombination Activating Gene-1 (Rag1)-/- and Rag2-/- mice, more evidence was
generated for cancer immunosurveillance by Robert Schrieber’s group. They proposed
a more comprehensive theory for how the immune system protects against tumor
development and how it manipulates the immunogenicity of tumors. This new theory
was termed cancer immunoediting and it consists of three major steps: 1) recognition
and elimination of malignant cells by the immune system (cancer immunosurveillance);
2) equilibrium between malignant cells and the immune system and 3) escape of
neoplastic cells that have reduced immunogenicity (13, 102, 141). After the cancer
immmunoediting theory was proposed several studies have generated strong evidence
that supports the idea that IFN, in particular IFN-I and IFN-II, play important roles
during the three phases of the cancer immunoediting process.
Studies using IFNAR1-deficient mice and antibody blockade of IFNAR1, showed
that loss of IFN-I signaling by the host increased the formation of 3-Methylcolantrene
(MCA)-induced tumors and abrogated the rejection of highly immunogenic MCAderived sarcomas in mice (142). Similar results were observed in mice deficient in IFN21

 signaling, indicating that both IFN-I and IFN-II play important, but not redundant roles,
in the intrinsic immune responses against tumor development (13, 102, 141, 143).
Moreover, Dunn and colleagues showed that responsiveness to IFN-I by host
hematopoietic cells, but not tumor cells, was necessary to induce tumor regression
(142). These results established a clear role for IFN-I during the cancer
immunosurveillance or elimination phase of the cancer immunoediting process.
The second phase of the cancer immunoediting process, known as equilibrium,
occurs when a balance between malignant cells and immune cells is maintained and
no clinical signs of tumor development may be noticeable. Work from Schreiber’s group
showed that this process can last for long periods of time and it is largely mediated by
adaptive lymphocytes and IFN-II (144). At the interface of the equilibrium phase and
the escape phase of cancer immunoediting is where the process of editing is thought to
occur. In this process the immune system’s attack on transformed cells induces the
development of less immunogenic transformed cells that can eventually escape
immune recognition. Importantly, IFN-I are also significant mediators in this process.
Schrieber’s group showed that around 40% of MCA tumors derived from IFNAR1-/mice were rejected when implanted into naive wild-type mice, suggesting that these
tumors conserved a highly immunogenic or unedited phenotype (142). Whereas MCA
tumors derived from wild-type mice grow rapidly when transferred into naïve wild-type
mice, having a less immunogenic phenotype (142). These results exposed important
functions of IFN-I to influence the immunogenicity of tumors.
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1.2.3 Anti-metastatic and immunostimulatory effects of IFN-I

IFN-I can induce an array of stimulatory effects on innate immune cells that
support their central functions during spontaneous anti-neoplastic immune responses.
Diamond and colleagues showed that IFN-I signaling is required for early anti-tumor
immune responses, as blockade of IFNAR1 during early tumor development failed to
induce tumor regression of immunogenic MCA tumors (51). Moreover, Tom Gajewski’s
group found that IFN-I production by hematopoietic cells, specifically CD11c+ DCs in
tumor-draining lymph nodes, is observed prior to generating tumor-specific CD8 T cell
responses (9). Moreover, mice deficient in IFNAR1 or STAT1 signaling fail to induce
tumor-specific T cell priming (51). Schreiber’s group also showed that responsiveness
to IFN-I signaling, specifically by innate immune cells, was critical for tumor rejection
and for the generation of tumor-specific CD8 T cells (51). Notably, CD8+ DCs and
CD103+ DCs were shown to mediate cross-presentation of tumor antigens to CD8 T
cells and loss of these specific DCs subsets abrogated rejection of tumors in mice (55,
145). In consequence, studies by several groups established the importance of IFN-I
responsiveness in Batf3+ DCs for accumulation of these APCs in tumors, crosspresentation of tumor-derived antigens, priming of antigen-specific CD8 T cells and
spontaneous rejection of tumors (9, 51, 146). Therefore, IFN-I production by innate
immune cells and signaling on specific DC subsets are essential for spontaneous
immune recognition and rejection of tumors.
IFN-I are considered a bridge between the innate and adaptive immune
responses because of their immunostimulatory effects on cells of both types of immune
responses. Importantly, IFN-I enhance maturation and antigen-presentation functions
of DCs (147). They also promote migration of DCs to lymph nodes and enhance cross23

presentation to CD8 T cells (146, 148). Macrophages also respond to IFN-I stimulation
by increasing inflammatory cytokines like IL-18 (149). Critical players that directly
mediate tumor-cell death, including cytotoxic CD8 T cells and NK cells, also depend on
IFN-I for maturation, enhanced effector functions and survival. For CD8 T cells, IFN-I
provide a third signal during activation to induce differentiation into cytolytic effectors
(150, 151). Furthermore, IFN-I signaling is necessary for CD8 T cell clonal expansion
and memory generation in settings of infection with LCMV (152). In this process IFN-I
promote survival of CD8 T cells during the antigen-driven proliferation phase. In
addition, IFN-I can protect CD8 T cells from NK cell-mediated death by changing the
expression of activating and inhibitory ligands for NK cells (153, 154).
It has long been appreciated that NK cells, the second subset of cytotoxic
lymphocytes that mediate tumor cell death, are targets of IFN-I. First, IFN-I treatment
can enhance NK cell cytotoxic activity in vitro (155, 156). Second, IFNAR1-/- and
IFNAR2-/- mice have decreased proportions of NK cells in the periphery and show
decreased survival after implantation with NK-cell sensitive tumors (157). In addition,
IFN-I mediate NK cell priming indirectly through the induction of IL-15 production and
trans-presentation by CD11c+ DCs (158). Lastly, NK cells from IFNAR1-/- and IFN--/mice display impaired cytotoxic functions against tumor cells in vitro (142, 157, 159).
Thus IFN-I are critical during NK cell maturation, priming and anti-tumor responses.
IFN-I are also important in prevention of metastasis formation. It is now clear
that both CD8 T cells and NK cells are important in preventing the dissemination of
cancer from a primary tumor site to other tissues, illustrated by studies where depletion
of CD8 T cells and NK cells causes increased metastatic dissemination to the bones in
breast cancer tumor models (160). Conversely, increased metastasis formation was
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also associated to loss of endogenous IFN-I signaling (161). Importantly, the control of
metastatic dissemination in these models of breast cancer was dependent on IFN-I
signaling and the presence of CD8 T cells and NK cells in the host. Thus IFN-s support
the control of metastasis development, likely through their actions on innate and
adaptive cytotoxic lymphocytes.

1.2.4 IFN-I therapy in cancer
IFN- was the first immunotherapeutic drug approved for the treatment of hairy cell
leukemia (82) and it subsequently showed promise as a therapy for melanomas,
myelomas, lymphomas and certain carcinomas inducing at least partial regression of
the disease (162). Moreover, IFN- has been used as adjuvant therapy after surgical
removal of melanomas (163) and due to their ability to inhibit angiogenesis, they have
been used as antiangiogenic agents in several tumor types including Kaposi’s
sarcomas (164). In bladder cancer IFN- is used in patients that fail to respond to BCG
therapy (165). Although initial success was observed when using IFN- in the
treatment of certain malignancies, the systemic side effects induced by this treatment
at high doses were particularly problematic and included fever, chills, weight loss,
anorexia and fatigue (166). Thus, with the generation of more specific targeted
therapies the use of IFN- in clinical settings has declined. However, as activation of
many other signaling pathways, including TLR stimulation and STING pathway
activation induce IFN-I production, the focus has now shifted to target the activation of
these pathways for the therapeutic benefits of IFN-I production and enhancement of
anti-tumor immunity.
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1.2.5 STING pathway in spontaneous and therapeutic responses to cancer
Recognition of pathogens and their products is an important function of innate
immune cells to generate specific immunity and protect the host from disease. In response
to PRR engagement, innate immune cells activate the transcription of important genes
including IFN-I to activate other immune cells to the threat. Of particular importance to the
work presented in this dissertation is the activation of a cytosolic DNA sensing pathway
known as the STING pathway. This pathway was first studied in the context of immune
recognition of DNA viruses and it was soon discovered to also be involved in immune
sensing of certain bacterial infections (167). In brief, cytosolic DNA is recognized by the
cyclic GMP-AMP synthase (cGAS) enzyme that generates a second messenger, cyclic
GMP-AMP (c-GAMP) (168, 169). c-GAMP activates the STING protein in the ER
membrane which induces the activation of IRF3 and its translocation to the nucleus where
it can upregulate transcription of IFN-I (132, 170, 171). Moreover, certain bacteria produce
cyclic dinucleotides that can directly activate STING and induce IFN-I production (172).
While, STING pathway activation is important for anti-viral and anti-bacterial immune
responses, recent findings shed light into its pivotal role in anti-tumor immune responses.
As discussed in the previous section spontaneous anti-tumor immune responses
and priming of cytotoxic T cells require IFN-I expression and signaling (9). However, it
wasn’t until recently that the specific mechanism by which innate immune cells sense
tumors and induce IFN-I production was discovered (173). Studies by Tom Gajewski’s lab
identified that recognition of tumor DNA, as a product of cellular death, in the cytosol of
innate immune cells induced the activation of the STING pathway and induced IFN-I
production which in turn promotes priming of CD8 T cells to tumor antigens (173) (Fig.2).
Moreover, activation of the STING pathway in tumor cells can also restrict tumor
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development as it can induce the production of proinflammatory cytokines, chemokines
and growth factors associated with decreased tumorigenesis and cellular senescence
(174-176). In addition, loss of STING signaling in tumor cells led to increased tumor growth
in part by decreased infiltration of cytotoxic lymphocytes in tumors (177-179).

Figure 2. Spontaneous tumor recognition is mediated by recognition of
dsDNA by the STING pathway in innate immune cells. Apoptotic tumor cells can
release dsDNA that can be recognized by cGAS in the cytosol of both tumor cells and
innate immune cells, like DCs. Recognition of dsDNA by cGAS leads to activation of
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STING which in turn upregulates the transcription of IFN-I. In the TME, IFN-I can promote
DC maturation and enhance CD8 T cell crosspriming both in the TME and in the tumor
draining lymph nodes. IFN-I can also promote cytolytic activity of CD8 T cells and NK cells
to promote tumor cell killing.
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STING signaling is important not only for the spontaneous anti-tumor responses but
also enhances responses to other therapeutic modalities including radiation therapy,
chemotherapy and immune checkpoint blockade (180-183). In brief, STING-deficient mice
failed to control tumor growth in response to radiotherapy and STING activation in DCs
induced IFN-I production that was required for antigen-specific CD8 T cell anti-tumor
responses (180). Interestingly, while radiotherapy induces STING pathway activation and
can promote anti-tumor responses, if used at high doses it can trigger down-regulation of
c-GAS/STING pathway in tumors by induction of DNA exonuclease TREX-1 to degrade
cytosolic DNA (184). In addition, activation of the STING pathway in cancer cells by
several chemotherapy agents including Poly (ADP ribose) polymerase 1 (PARP1) and
checkpoint kinase 1 (CHK1) inhibitors was essential for their therapeutic effects (181, 182).
Moreover, STING signaling was essential for the therapeutic response to anti-PD-L1
treatment in melanoma tumors (183). Altogether, these findings strongly suggest that
STING activation in TME plays essential roles in enhancing spontaneous and therapeutic
anti-tumor responses and should be the focus of new therapeutic approaches.
Due to the strong rationale for inducing STING activity in the TME to improve antitumor responses several approaches were undertaken to induce intratumoral activation of
the c-GAS/STING pathway (180, 185, 186). As cyclic dinucleotides produced by
mammalian cells and bacterial dinucleotides, like 2’3’-c-GAMP and cyclic diguanylate
monophosphate (c-di-GMP), could induce STING activation (168, 172, 187, 188), they
were first used as intratumoral therapies. 2’3’-c-GAMP was used in combination with
radiotherapy in the treatment of MC38 colon carcinomas and potentiated the anti-tumor
effects of radiotherapy by enhancing CD8 T cell functions (180). Furthermore, c-GAMP
delivery into melanoma and colon tumors in mice, alone and in combination with
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checkpoint blockade for PD-1 and CTLA-4, induced tumor growth control and enhanced
CD8 T cell responses (189). c-di-GMP was also used alone and in combination with OVApeptide vaccination and enhanced survival of glioma-bearing mice (185).
With the success of natural STING agonists in preclinical tumor models, the focus
shifted to other compounds and designing novel synthetic dinucleotides that could act as
STING agonists and be safely delivered to the tumor. One of the first compounds studied
was 5’-6’ dimethylxanthenone-4-acetic acid (DMXAA) that binds to mouse STING but not
human STING (190). Tom Gajewski’s group showed that intratumoral delivery of DMXAA
into melanoma tumors efficiently primes CD8 T cells for rejection of established tumors
(186). They also developed novel cyclic dinucleotides that bind to human STING and
enhance local and systemic anti-tumor responses to treated and distant secondary tumors
(186). They designed a novel cyclic dinucleotide first termed ML RR-S2 CDA, now known
as ADU-S100, which is currently being tested in clinical trials in combination with other
immunotherapies (191-193). Intratumoral STING agonists have also been evaluated in
preclinical models in combination with other immunotherapy strategies including immune
checkpoint inhibitors and CAR T cell therapy (189, 194, 195).
Many other STING agonists have been developed and some of them are being
studied as intratumoral therapeutics in combination with other cancer therapies (196, 197).
Nevertheless, recent reports suggest that considerations should be taken in regard to
dosing strategies to ensure that combination strategies with immune checkpoint inhibitors
and intratumoral STING agonists induce robust activation of CD8 T cells in tumors and
long term maintenance of anti-tumor immunity (198).
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STING activation is important for sensing tumors and activating spontaneous and
therapeutic anti-tumor immune responses by the production of IFN-I. Importantly, we
showed that STING activation induces production of sIL-15 complexes in the circulation in
response to cyclic dinucleotides and after total body irradiation (TBI) (199, 200), thus in
this dissertation I investigated if STING activation in the TME could enhance IL-15
production in tumors and the results of these experiments will be discussed in more detail
in Chapter 3.
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1.3 Interleukin-15 (IL-15): a key cytokine for cytotoxic lymphocyte responses
1.3.1 IL-15 discovery and functions
IL-15 is a 14-15 kDa cytokine discovered in 1994 as a T cell growth factor,
similar in structure and function to IL-2 (201, 202). Although IL-2 and IL-15 share no
sequence homology, they have similar protein structures and functions in vitro. Both
cytokines can stimulate T cell proliferation, NK cell cytotoxicity and induce lymphokineactivated killer cell activity (201, 203-206). Initial studies using northern blots, indicated
that IL-15 mRNA is widely expressed in many tissues including placenta, skeletal
muscle, heart, liver, lungs, brains, spleens, kidneys and intestines but detection of IL-15
protein was very low (201, 206, 207). In fact, detection of IL-15 protein in serum or cell
culture supernatants was minimal even when cells were stimulated with inflammatory
mediators (208-210). These findings hinted to sophisticated mechanisms of IL-15
protein expression regulation.
Studies using antibodies against the IL-2 receptor (IL-2R) subunits
demonstrated that IL-15 binds to the IL-2R and common gamma chain (c) complex
but does not bind to the IL-2R subunit (206). On the other hand, IL-15 has its own IL15R chain that binds to IL-15 with very high affinity (Ka=1011 M-1) and its mRNA
expression was detected in many tissues, largely overlapping with IL-15 mRNA
expression (211). While IL-15 and IL-2 can form heterotrimeric receptor complexes with
IL-2R, c and their respective R chains, the IL-15R and IL-2R chains are not
essential for mitogenic signaling through the IL-2R and c complex (208, 212).
Importantly, interaction of either cytokine with the IL-2R/c complex induces signaling
through the JAK1/JAK3 STAT3/STAT5 pathway (213). Suggesting that IL-2 and IL-15
signaling is almost identical; however, the different expression patterns of mRNAs for
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these cytokines and the difficulties in detecting IL-15 protein in tissues pointed to
potentially different functions in vivo and different regulatory mechanisms limiting their
expression.
While IL-2 protein is expressed primarily by activated T cells and is primarily
regulated at the transcription level, the low amounts of IL-15 protein, that could be
detected in tissues and in stimulated cells, hinted at more rigorous regulatory
mechanisms for IL-15 protein expression. In fact, several studies confirmed that IL-15
expression is subject to transcriptional, translational and post-translational regulation.
This regulation is mediated in part by multiple start sites in the 5’ UTR region, two
different signal peptides and regulatory elements found in the 3’UTR regions of the IL15 gene (210, 214, 215).
In terms of biological activity, studies using knockout mouse models provided
evidence for distinct in vivo biological functions for IL-15 and IL-2. Mice that lack IL-2 or
IL-2R develop a fatal autoimmune disorder, while thymic development of adaptive
lymphocytes remains largely unaffected, indicating that IL-2 plays an important role in
regulation of autoreactive immune cell populations (216-218). In contrast, IL-15 -/- and
IL-15R-/- mice do not develop any autoimmunity but show defects in specific immune
cell compartments (219, 220). Further differences in function between IL-15 and IL-2
include the major roles of IL-2 in Fas-mediated activation-induced cell death (AICD) of
activated CD4 T cells and in the thymic development and long-term survival of Tregs in
the periphery (221-224). In contrast, IL-15 can inhibit AICD mediated by IL-2 and
TRAIL-mediated apoptosis by inducing the expression of anti-apoptotic molecules like
Bcl-2 and Bcl-XL (225-227).
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Studies using IL-15-/- and IL-15R-/- mice demonstrated that IL-15 plays
important roles in the development of several subsets of lymphocytes including NK
cells, NKT cells, CD8+ intra-epithelial lymphocytes (IELs) and memory CD8 T cells
(219, 220). IL-15-/- mice lack functional mature NK cells, and have a marked decrease
in NKT cells in the thymus and periphery, CD8 T cells with a memory phenotype and
CD8+ IELs (219). IL-15R-/- mice are lymphopenic and show a similar phenotype to
IL-15-/- mice (220). Importantly, IL-15-/- mice are relatively healthy but when
challenged with vaccinia virus they are not able to clear the infection and subsequently
die (219), suggesting that IL-15 is crucial for host defense against viral infections.

1.3.2 Mechanisms of action of IL-15
The high binding affinity of IL-15R to IL-15, their similar mRNA expression
patterns across many tissue types and immune cells and the similar phenotypes of IL15-/- and IL-15R-/- mice suggested a possible requirement for the interaction of IL-15
with IL-15R for its actions on IL-15 responsive cells. As IL-15R expression was
detected in CD8 T cells and NK cells (228, 229), studies dissecting if co-expression of
IL-15R by IL-2R/c expressing cells was necessary for IL-15 responsiveness were
next undertaken. Unexpectedly, IL-15R expression by either NK cells or CD8 T cells
was not required for their survival or proliferation in response to IL-15 stimulation (230233). However, when transferred into wild-type hosts or bone marrow chimeras, IL15R-/- lymphocytes differentiated, proliferated and survived when IL-15R was
expressed by radiation-sensitive hematopoietic cells (230, 231, 233). The results from
the studies described above led to the hypothesis that expression of IL-15R on
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immune cells different from lymphocytes, was necessary for IL-15-mediated effects in
vivo. Accordingly, studies by Schluns et al subsequently showed that bone marrow
(BM)- derived and parenchymal cells expressing IL-15R were required for naïve CD8
T,  T cell, NK and NKT cell development (234). In contrast, expression of IL-15R by
BM-derived cells was required for memory CD8 T cell differentiation and maintenance
through basal homeostatic proliferation (234).
As IL-15R expression by non-lymphocytic cells is required for IL-15 functions in
vivo, this peculiar requirement pointed to a likely unique mechanism of action for
endogenous IL-15. Importantly, in vitro studies investigating the role of IL-15R on IL15 signaling showed that membrane bound IL-15/IL-15R complexes could act in trans
to stimulate proliferation of neighboring cells that express the IL-2R/c complex (235).
This new mechanism of action was termed “transpresentation” and provided a rationale
for why IL-15R expression by cells, other than CD8 T cells and NK cells, was
necessary for IL-15-mediated effects. Subsequently, it was shown using elegant bone
marrow chimeras studies that expression of IL-15 and IL-15R by the same cell was
necessary for development and basal proliferation of mature NK cells and memory CD8
T cells (236, 237). Thus, transpresentation is a unique mechanism of action, attributed
to IL-15, that requires direct cell to cell contact of IL-15 producing cells with IL-15
responsive cells (Fig. 3A).
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Figure 3. Mechanisms of action of IL-15. The IL-15/IL-15R complex is
formed intracellularly in the endoplasmic reticulum and shuttled to the cell surface of IL15 expressing cells including myeloid cells, stromal and epithelial cells. IL-15 exerts its
immunostimulatory effects mainly on CD8 T cells and NK cells. A) During steady-state,
trans-presentation of IL-15 by IL-15R, requiring direct cell-to-cell contact with IL-2/IL15R and c expressing cells is the main signaling mechanism. B) During inflammation,
the IL-15/IL-15R complex is cleaved from the cell surface by proteases and can send
paracrine signals to nearby cytotoxic lymphocytes.
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The findings discussed in the previous paragraphs pointed to transpresentation
of IL-15 as an important mechanism regulating IL-15 effects on adaptive immune cells.
Still, other studies showed that in response to inflammatory signals the IL-15/IL-15R
complex can be cleaved from the cell surface from the IL-15 producing cells and
potentially induce paracrine signaling on cells that express the IL-2R/c complex (238240). Hence, pointing to a second possible mechanism of action in which IL-15 and IL15R form soluble complexes that act on nearby cells (Fig. 3B).
Cleavage of cell surface IL-15/IL-15R cell complexes is likely mediated by
proteases and the specific metalloproteases that mediate the cleavage in vivo are still
being studied. Several analyses pointed to the metalloprotease A Desintegrin and
Metalloprotease 17 (ADAM17) as a possible mediator of this cleavage. ADAM17 is
known to mediate the cleavage of membrane bound TNF- and several other
substrates, this in part because ADAM17 is expressed in many tissues (241-243).
Importantly, ADAM17 can cleave IL-15R from the cell surface of cells in vitro (239,
244). Thus, our group sought to study the role of ADAM17 in generating soluble IL15/IL-15R complexes (sIL-15 complexes). We found evidence that ADAM17 mediates
the cleavage of IL-15/IL-15R complexes from the cell surface of bone marrow derived
DCs in response to IFN- stimulation (199). However, when ADAM17 expression was
abrogated in a tamoxifen-inducible knockout mouse model we found that ADAM17
expression was only partially required for the generation of sIL-15 complexes in
response to Poly I:C, but was not necessary for the IFNAR-independent generation of
sIL-15 complexes in vivo (199). Consequently, the evidence suggests that other
metalloproteases could also be mediating the generation of sIL-15 complexes in vivo.

37

Regardless of the nature of the IL-15 complexes, whether soluble or membranebound, it is clear that IL-15R expression by IL-15-producing cells could be important
not only mediating the effects on IL-15-responsive cells but also in enhancing the
stability of the cytokine signal. Thus, it was not surprising that studies revealed that coexpression of IL-15 and IL-15R by the same cell is necessary to stabilize the IL-15
protein intracellularly by forming an IL-15/IL-15R complex in the endoplasmic
reticulum that is then shuttled to the cell surface (238, 245). Accordingly, cell surface
expression of IL-15 is tightly regulated by coupling to IL-15R and once on the cell
surface the IL-15/IL-15R complex can induce juxtracrine signaling or be cleaved and
potentially induce paracrine signaling.

1.3.3 IL-15 functions during homeostasis and inflammation
Studies focusing on ablation or selective expression of IL-15R on specific cell
subsets provided the first evidence of the roles of specific cell types transpresenting IL15 in lymphocyte development, maintenance and survival during steady state (246250). Studies using IL-15R-/- mice and cell specific IL-15R transgenic mice
determined that DCs and macrophages transpresent IL-15 to support the development
and maintenance of mature NK cells and homeostatic proliferation of memory CD8 T
cells (247, 248, 251). Importantly, intestinal epithelial cells trans-present IL-15 to drive
development, differentiation and survival of CD8+ IELs (250).
In addition to myeloid cells, other cells of non-hematopoietic origin including
keratinocytes, liver, kidney, skeletal muscle cells, microglia and thymic epithelial cells
express IL-15 mRNA (201, 206, 207, 246, 250, 252-254). In keratinocytes IL-15 acts a
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factor that promotes survival and proliferation (254). In the kidney, IL-15 serves as a
survival factor to protect tubular epithelial cells from transformation and cell death (255,
256). In skeletal muscle cells, IL-15 is thought to act as a pleiotropic myokine that
regulates the oxidative metabolism of muscle fibers and reduces adipose tissue mass
(257). Studies where skeletal muscle-specific IL-15 was overexpressed showed
increased mitochondrial mass and activity in the adipose tissue, pointing to a role for
IL-15 in the interaction between muscle and adipose cells (257). Consequently, IL-15 is
not only important for development and survival of cells of the immune compartment
but also plays critical roles promoting survival and metabolism of many other cell types.
After the discovery of IL-15 it was soon demonstrated that activation of
monocytes, and macrophages with TLR agonists, including LPS, Poly:IC and IFN-I led
to upregulation of IL-15 mRNA expression and protein production (203, 258-260).
Other studies also showed that in vivo delivery of these inflammatory mediators could
induce IL-15 mRNA expression (156, 261). As these inflammatory proteins are
produced by infectious pathogens it was important to use viral models of infection to
investigate the roles of IL-15 during inflammation.
To this extent, studies in IL-15-/- mice showed that in absence of IL-15 the mice
succumbed to infections with vaccinia virus and genital herpes simplex virus type 2
(HSV2). These poor responses were mostly due to the lack of mature NK cells and
defects in NKT cells in these mice (219, 262). Studies using murine cytomegalovirus
(MCMV) showed that IFN-I and IL-15 were necessary for the activation, cytotoxic
activity and survival of proliferating NK cells (156). Moreover, IL-15 expression was
necessary for the generation of antigen-specific memory CD8 T cells in a vesicular
stomatitis virus (VSV) model of infection (228). Importantly, in settings of infection with
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VSV and lymphocytic choriomeningitis virus (LCMV) IL-15 was required for the
generation and long-term maintenance of memory CD8 T cells (228, 232). Additionally,
IL-15 has been shown to have protective effects against bacterial infections like
Mycobacterium tuberculosis, Salmonella enterica and in sepsis models (263). Taken
together, all these findings demonstrate that IL-15 plays essential roles in generation of
effective anti-viral and anti-bacterial immune responses by CD8 T cells and NK cells.
IL-15 has also been shown to promote CD8 T cell and NK cell migration to sites
of inflammation (264-266). IL-15 produced in the lung airways of influenza infected
mice was important to recruit effector CD8 T cells to the site of infection and treatment
with exogenous IL-15/IL-15R complexes was enough to restore the frequency of
effector CD8 T cells in IL-15-/- mice after influenza infection (266). A follow-up study by
the same group demonstrated that IL-15 mediated the recruitment of NK cells to the
lung airways after influenza infection (265). These results support early in vitro studies
that showed that IL-15 could act as a chemoattractant to T cells and NK cells and could
induce the expression of chemokines and chemokine receptors on T cells (264, 267269).
As IL-15 stimulates NK cells and CD8 T cells, it is not surprising that IL-15 has
also been associated with states of overt immune cell activation. Transgenic mice that
overexpress IL-15 develop a form of T-cell leukemia and IL-15 expression is linked with
pathology observed in several inflammatory and autoimmune diseases including
rheumatoid arthritis, psoriasis, Celiac Disease, inflammatory bowel diseases, and
multiple sclerosis (270-273). IL-15 is not only an important regulator of cytotoxic
lymphocyte development and homeostasis but is an important inflammatory mediator
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during overt states of inflammation including bacterial and viral infections and
inflammatory and autoimmune diseases.

1.3.4 IL-15 regulation
IL-15 expression during homeostatic conditions is tightly regulated not only at
the transcription and post-transcriptional level but also by its interaction with IL-15R.
These mechanisms ensure a low constitutive level of lL-15 is available for the
development and survival of lL-15 responsive cells. During inflammation, IL-15
production is increased and generation of sIL-15 complexes is also observed. In this
section I will discuss several mechanisms by which IL-15 responses are regulated in
situations of immune activation and in response to several inflammatory stimuli.
As mentioned previously, soon after the discovery of IL-15 it was observed that
in response to inflammatory mediators including TLR4 and TLR3 agonists, like LPS
and Poly I:C, both IL-15 mRNA and protein expression is upregulated (203, 258-260).
In vitro stimulation with LPS and Poly I:C increase IL-15 mRNA expression by
macrophages and DCs (240, 259, 261). In vivo stimulation with these TLR agonists
induces production of IL-15/IL-15R complexes by DCs (240). Moreover, our group
and others showed that VSV infection, CD40 stimulation and total body irradiation can
also enhance IL-15 expression and production of sIL-15 complexes (158, 199, 274,
275).
During infections or because of TLR stimulation, IFN-I are generated and
positively regulate IL-15 production. Both in vitro and in vivo treatment with IFN-I
upregulates transcription and cell surface expression of IL-15 and IL-15R (259, 261,
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276-278). Importantly, our group showed that in vivo treatment with IFN- induces the
production of sIL-15 complexes found in the sera of mice (199). Importantly, we
showed that the upregulation of sIL-15 complexes observed upon stimulation with IFN, Poly I:C, agonists of the STING pathway and total body irradiation was dependent
on IFN-I signaling, as generation of sIL-15 complexes was impaired in mice deficient in
the Interferon Alpha Receptor 1 (IFNAR-/-) (199, 200) . Although IFN-I signaling is
required for cell-surface IL-15/IL-15R expression and upregulation during VSV
infection and during TLR4 stimulation (158, 277), our study revealed that other
signaling pathways other than IFN-I signaling may be responsible for generation of sIL15 complexes during VSV infection and upon CD40 stimulation (199). These findings
suggest that IL-15 production in response to inflammation is regulated by IFN-I
dependent and independent pathways. In Chapter 3 of this dissertation I will show how
IFN-I regulate the production of sIL-15 complexes early during tumor development and
how this regulation correlates with tumor-infiltrating lymphocyte numbers.
1.3.5 Better models for IL-15 detection
Since detection of IL-15 protein in vivo proved difficult using conventional
hybridization methods, the development of novel techniques and mouse models for
detecting IL-15 protein were important to clarify IL-15 requirements and sources. To
this extent, the generation of two different transgenic IL-15 reporter mouse models has
aided in the quest to confirm the identity of IL-15 producing cells (277-279). The first IL15 GFP reporter mouse model was generated using a bacterial artificial chromosome
(BAC) in which GFP is expressed under the control of the IL-15 promoter (277). The
second transgenic IL-15 reporter model was generated by introducing a modified BAC
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that contains the IL-15 gene locus, where IL-15 is linked to GFP using a 2A peptide
(279). In the first transgenic model, GFP expression reflects the activity of the IL-15
promoter, modeling transcription of IL-15. The second transgenic reporter model serves
as a model for IL-15 translation, where GFP expression is concurrent with IL-15
expression however, it does not mimic the trafficking and secretion of IL-15.
Studies using these transgenic IL-15 reporter mouse models confirmed that IL15 expression in cells of hematopoietic origin is largely confined to myeloid cells. IL-15
reporter expression was confirmed in basophils, mast cells, eosinophils, neutrophils,
monocytes, macrophages and in several subsets of DCs including CD8+ DCs and
CD11c+ DCs, albeit at very low levels in the latter (280). Moreover, the expression of
IL-15 reporter was observed during steady state conditions and could be further
enhanced in certain cell subsets after infection with vaccinia virus or after total body
irradiation (200, 280). Moreover, the development of more sensitive enzyme-linked
immunosorbent assays (ELISA), demonstrated that the physiological configuration of
the IL-15 cytokine consists of either membrane-bound or sIL-15 complexes, as soluble
IL-15 is not found in the circulation (274). These new models provided an important
avenue for our group to study endogenous IL-15 production, specific cellular sources
and regulation of IL-15 expression in the setting of tumor development (281). In
Chapter 3 of this dissertation, I will discuss in detail the findings of our most recent
published work (281) .
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1.4 Therapeutic potential for IL-15 in cancer
The idea of using cytokines as therapies for cancer was solidified with the
approval of IFN- as therapy for hairy cell leukemia by the FDA in 1986 (282).
Subsequently IFN- was approved for treatment of melanoma, Kaposi sarcoma and
other hematological malignancies (283, 284). In 1992, IL-2 became the second
cytokine to receive approval as a cancer immunotherapy for metastatic renal cell
carcinoma, and in 1998 it was approved for treatment of advanced melanoma (285,
286). Unfortunately, both IFN- and IL-2 had to be administered at high doses due to
their short in vivo half-life, had low response rates and provoked severe adverse effects
(283). Since then several cytokines including IL-12, GM-CSF, IL-21 and IL-15 have
also been studied as monotherapies for cancer (283, 284). The focus of this section is
to discuss the current therapeutic formulations of IL-15 studied as cancer therapeutics.

1.4.1 Recombinant IL-15 as cancer monotherapy
As mentioned previously, IL-15 shares similar functions to IL-2, including
inducing proliferation of activated T cells and in differentiation of effector T cell subsets.
In contrast to IL-2, IL-15 acts as a survival factor for T cells at different stages of
development, does not promote maintenance of Tregs and its actions in vivo
preferentially stimulate CD8 T cells and NK cells, key cytotoxic mediators of tumor cell
death. Moreover, in pre-clinical studies in mice IL-15 administration or overexpression
induced potent anti-tumor responses by CD8 T cells in metastatic colon carcinomas
and fibrosarcomas, rhabdomyosarcomas and melanomas (275, 287-289). These
findings provided the first evidence of the potential of recombinant IL-15 as a cancer
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therapeutic. These IL-15 attributes led to its consideration as one of the most promising
agents for cancer immunotherapy by the National Cancer Institute in 2008.
Studies in non-human primates established the safety of recombinant human
(rh) IL-15 administration. Delivery of IL-15 at a dose of 20 g/kg/day for 10-12 days via
intravenous (i.v.) bolus, continuous intravenous (c.i.) or subcutaneous (s.c.) infusions
led to ~10 fold increase in circulating NK cells and between 10 to 100 fold increase in
number of circulating effector memory CD8 T cells (290-292). While no capillary leak
syndrome or hemodynamic instability were observed in these studies, grade 3 and 4
transient neutropenia was observed with i.v. bolus administration of rhIL-15 (290).
These findings in non-human primates provided the rationale to initiate clinical trials for
safety of rhIL-15 in humans.
In the first phase-I clinical trial for rhIL-15 in adults with metastatic melanoma
and renal cell carcinoma, daily i.v. administration of rhIL-15 led to a 10-fold expansion
of NK cells in patients treated with a dose of 3g/kg of rhIL-15 (293). However,
increases in other inflammatory cytokines including IL-6 and TNF- were found upon
rhIL-15 administration at high doses. The increase in inflammatory cytokines was
accompanied by acute toxicities including hypotension, fever and chills. Thus, it was
concluded that the maximum tolerated dose for daily infusion of rhIL-15 was 0.3g/kg
and with this dose the effects observed in NK cell increases were reduced to ~3-fold
expansion.
Two other phase I clinical trials for safety and dose escalation of continuous
infusion and s.c. administration of rhIL-15 were started. Recently, the phase-I dose
escalating trial for daily s.c. administration of rhIL-15 in patients with advanced solid
tumors was completed (294). It was determined that the maximum tolerated dose for
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s.c. daily administration of rhIL-15 was 2 g/kg, demonstrating that s.c. delivery of rhIL15 allowed for significant dose escalation when compared to bolus i.v. administration.
Increases in circulating NK cells and CD8 T cells were observed to a similar extent as
with bolus i.v. administration of rhIL-15. This trial was terminated early because one of
the participants developed a severe adverse event associated with chest pain and
hypotension. Importantly, in either of these trials significant clinical responses were
observed, only maintenance of stable disease in a subset of patients. These trials shed
light into some of the limitations that must be overcome to achieve functional anti-tumor
responses by IL-15 monotherapy including its short half-life, the high-doses required for
therapeutic efficacy and the increase in other inflammatory cytokines that could cause
undesired side-effects.

1.4.2 IL-15/IL-15R agonists
To address the limitations of rhIL-15, several formulations of IL-15 agonists have
been developed including mimics of the sIL-15 complexes. Initial studies suggested
that a natural soluble form of the human IL-15R could act as an IL-15 antagonist by
binding to membrane bound IL-15 (239). However, in vitro and in vivo studies in mice
showed that treatment with IL-15 bound to IL-15R induces proliferation of memoryphenotype CD8 T cells and NK cells and enhances the anti-tumor activity of IL-15 (295298). What is more, these mimics of sIL-15 complexes are more potent than IL-15
treatment alone in inducing proliferation of NK cells and CD8 T cells in vivo (295-297,
299). Since IL-15/IL-15R heterodimer is the major form of IL-15 protein detected in
the circulation of both humans and mice (274), it was important to generate
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recombinant molecules that mimicked the natural configuration of the IL-15/IL15R complex.
Several different strategies have been used to mimic the endogenous IL-15/IL15R complex. The first strategy was developed by Pavlaki’s group, known as
heterodimeric IL-15, which consists of recombinant IL-15/ IL-15R complexes that
retain the native structure of the cytokine (300). To achieve this, human cell lines were
engineered to overexpress the natural form of IL-15/IL-15R complexes. Studies in
mice revealed heterodimeric IL-15 has an increased half-life of 4 hours when compared
to less than 30 minutes for E. coli derived rhIL-15 (300). Heterodimeric IL-15 also
induces potent CD8 T cell and NK cell proliferation, indicating superior bioactivity of
heterodimeric IL-15 when compared to rhIL-15. Additionally, systemic treatment with
heterodimeric IL-15 can induce activation, enhanced cytotoxicity and increased
migration of antigen-specific CD8 T cells in a mouse model of adoptive cell therapy
(301). This particular IL-15 agonist is currently in clinical trials as a systemic
monotherapy and in combination with anti-PD-1 checkpoint inhibitors for metastatic
solid tumors (193).
A second strategy used mostly in pre-clinical models of cancer are recombinant
soluble IL-15/IL-15R−Fc complexes (rsIL-15c). This is achieved by combining
recombinant IL-15 with a fusion protein of soluble mouse IL-15R linked to the Fc
portion of human IgG1 (296). Similar to heterodimeric IL-15, the in vivo half-life of rsIL15c was significantly increased to ~20 hours and systemic delivery of these complexes
increased 50 to 100-fold the proliferation and expansion of memory CD8 T cells and
NK cells populations when compared to rhIL-15 (295-297, 299). Lastly, rsIL-15c show
increased anti-tumor activity over IL-15, evidenced by their ability to limit tumor growth,
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decrease metastatic spread and improving survival in metastatic melanoma and
spontaneous pancreatic tumor models (295-298). The two types of soluble IL-15/IL15R mimics shed light on the effects of enhancing the stability and half-life of IL-15 by
linking it to IL-15R, prompting others to focus on targeting specific domains of the IL15R to simplify the development of more stable and potent IL-15 agonists.
Studies dissecting the interaction of IL-15R to IL-15 determined that while the
cytoplasmic domain of IL-15R is not necessary for transpresentation of IL-15 (302),
the sushi domain of the IL-15R protein is however responsible for the high-affinity
binding to IL-15 (303). The sushi domain of IL-15R is a 65 amino acid motif at the Nterminal domain of the IL-15R protein which mediates protein-protein interaction with
IL-15. A fusion protein called receptor-linker- IL-15 (RLI) was developed by combining
human IL-15 to amino acid 1-77 of the sushi domain of IL-15R using a 20 amino acid
linker peptide (304). This new agonist showed an increased half-life of ~3 hours and
proved effective in enhancing anti-tumor immune responses by increasing mouse
survival and limiting metastatic spread of melanoma tumors to the lungs and liver (305).
Although RLI enhanced anti-tumor functions it only partially inhibited tumor growth and
in a model of colorectal cancer it was only effective delaying tumor growth when
systemic monotherapy was started early during tumor development (306). Delayed
treatment with RLI proved unsuccessful delaying tumor growth and this was correlated
with an exhausted phenotype of CD8 TILs. Thus, RLI was used in combination with an
anti-PD-1 checkpoint inhibitor and they acted synergistically to increase survival and
improve complete response rates (306).
Taken together these findings show that conjugating IL-15 to the entire IL15R protein or just the sushi domain of IL-15R enhances the bioavailability of IL-15,
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by stabilizing the protein and increasing its half-life. Although these IL-15/IL15R agonists prove potent inducers of CD8 T cell and NK cell anti-tumor responses
that limit tumor growth and metastatic spread, monotherapy with IL-15 is not sufficient
to completely eradicate tumors, suggesting that combination therapy with checkpoint
inhibitors and other immunotherapies are the next logical steps to achieve complete
remission of tumors. Currently, an ongoing phase I/Ib clinical trial is testing the safety
and responsiveness of RLI as a monotherapy and in combination with an anti-PD-1
checkpoint inhibitor for advanced metastatic tumors (307).
Another approach to develop IL-15 agonists has also been explored and a new
IL-15R/c agonist is under development by Nektar Therapeutics (308). This new
agonist, NKTR-255 is a recombinant human IL-15 protein that is conjugated to a
polyethylene glycol polymer and it is currently being investigated in preclinical studies
with non-human primates and mice and in combination with monoclonal antibodies in a
phase I clinical trial (309, 310). I will discuss more about this agonist and its use as an
intratumoral agent in Chapter 4 of this dissertation.
The last IL-15/IL-15R agonist that I will discuss is another fusion protein ALT803, which was recently renamed as N-803, that has shown great potential as a potent
immunotherapy for cancer. This fusion protein was created by linking a mutated version
of IL-15 (IL-15N72D) to a dimer of IL-15R sushi domain-IgG1 Fc fusion protein (311).
IL-15N72D, is a mutated IL-15 peptide in which an asparagine to aspartic acid amino
acid substitution increases biological activity of this polypeptide over IL-15 (312). N-803
has an increased half-life of ~25 hours in mice and potently enhances CD8 T cells and
NK cells proliferation and activation (311, 313). Surprisingly, N-803 proved to have
increased anti-tumor activity over IL-15 in a variety of liquid and solid tumors (313-318).
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In models of multiple myeloma N-803 induced a reduction of 90% of myeloma cells in
the bone marrow and prolonged survival of myeloma-bearing mice (313). It also
protected mice from a second tumor challenge in a CD8 T cells-dependent manner.
Lastly, it promoted proliferation and expansion of memory-phenotype CD8 T cells and
increased their in vivo secretion of IFN- (313). Potent anti-tumor responses against
solid tumors by N-803 were observed in animal models of melanoma, colon
carcinomas, bladder cancers, glioblastomas, breast and ovarian cancers (313-317,
319). In particular, N-803 increased the infiltration of CD8 T cells into brain and bladder
tumors, supporting a role for IL-15 in promoting TIL infiltration (314, 316).
The surprising efficacy of N-803 across multiple tumor types increased the
interest in developing this IL-15/IL-15R superagonist as a clinical reagent. Importantly,
although systemic administration of N-803 could increase the circulating levels of other
inflammatory cytokines, including INF- and TNF-, no systemic toxicities were
observed (315). Moreover, systemic administration of N-803 in non-human primates
showed that its half-life was increased to ~8 hours and no significant adverse events
were observed with treatment (317). The results from the preclinical studies in mice
and non-human primates propelled the study of N-803 in several clinical trials as a
monotherapy or in combination with checkpoint inhibitors and adoptive cell therapies
across a multitude of tumor types (Lists of recent clinical trials for N-803 can be found
in (320, 321)). Importantly, due to the promising results from two clinical trials (322,
323) an intravesical combination treatment using Bacillus Calmette-Guerin (BCG) and
N-803 received the breakthrough therapy designation by the FDA for patients with
BCG-unresponsive non-muscle invasive bladder cancers (324).

50

1.4.3 IL-15 agonists in combination with other immunotherapies for cancer
Cancer immunotherapy strategies, whose goal is to activate the patient’s
immune system to react against malignancies, have come a long way since William
Coley’s 1890’s first immunotherapeutic trial using live and attenuated bacteria injected
into patients’ tumors (325). After Coley’s first trial, in which he observed spontaneous
regression in hundreds of patients of several types of malignancies, several decades
passed before interest in cancer immunotherapy was renewed and thus progress was
somewhat slow. Nonetheless, several types of immune based therapies have become
more widely developed and accepted including monoclonal antibodies, immune
modulators, cancer vaccines, adoptive cell therapy and the immune checkpoint
inhibitors. In this section I will discuss how IL-15 has been used in combination with
several immunotherapy strategies including adoptive cell therapy and checkpoint
inhibitors for treatment of different cancers.
Conventional adoptive cell therapy consists of isolating T lymphocytes from
patient tumor samples or blood and expanding them to great numbers to reinfuse them
back into the patient in the hopes that they will recognize specific antigens produced by
the individual patient’s tumor and induce tumor cell death via cytotoxic mechanisms.
This first type of adoptive cell therapy is commonly referred to as Tumor-Infiltrating
Lymphocyte (TIL) therapy. However, other types of adoptive cell therapy require the
genetic manipulation of these lymphocytes to engineer a transgenic TCR or a chimeric
antigen receptor (CAR) on the surface of the lymphocytes that recognizes a specific
antigen expressed primarily by tumor cells. These therapies are known as engineered
TCR therapy and CAR T cell therapy.
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IL-15 has been used for the ex vivo expansion of T cells during TIL therapy (289,
326). Moreover, TILs expanded in the presence of IL-15 maintained a central memory
T cell phenotype and migrate better into tumors than IL-2 expanded TILs (289, 327). IL15 can also restore responsiveness to antigens in tolerant CD8 TILs and promote
tumor clearance (328-330). Moreover, leukemia and glioma-specific CAR T cells
engineered to express IL-15 have improved proliferation and survival and better antitumor responses than conventional CAR T cells (331-333).
NK cells are currently being studied for adoptive cell therapies using
haploidentical NK cells, autologous NK cells and CAR NK cells for the treatment of
liquid tumors including acute myeloid leukemia and multiple myeloma (334-336). To
this extent combination therapy using rhIL-15 in combination with adoptive NK cell
therapies including haploidentical and autologous NK cells have been tested in several
clinical trials (NCT01875601, NCT02395822, NCT01385423, (336)). Moreover, cord
blood derived CD19 CAR NK cells were engineered to express IL-15 and this addition
enhanced their killing activity against leukemia cell lines and improved survival in a
mouse model of lymphoma (335). These CD-19 CAR NK cells were tested in a phase
I/II clinical trial in patients with relapsed or refractory non-Hodgkin’s lymphoma and
chronic lymphocytic leukemia with no adverse effects and responses in 8 out of 11
patients, including 7 complete remissions (337).
In addition to adoptive cell therapies, immune checkpoint blockade strategies
have also been studied in combination with systemic treatments with IL-15 and its
agonists in both preclinical and clinical studies. The rationale for using these
combination strategies is based on the upregulation of immune checkpoints including
CTLA-4, TIGIT, TIM3 and PD-1 on T cells (338-340). In preclinical models of prostate
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and colon cancers rhIL-15 was used in combination with anti-CTLA-4 and anti-PD-L1
mAb and the triple combination enhanced the anti-tumor activity of rhIL-15 and
enhanced mouse survival (341, 342). Similarly, rsIL-15c and N-803 were evaluated in
combination with anti-PD-1/PD-L1 mAbs in mouse tumor models of colon cancer and
triple negative breast cancers and the combination enhanced responses to anti PD1/PD-L1 therapy (343, 344). Lastly, both rhIL-15 and N-803 have been tested in clinical
trials in combination with immune checkpoint blockade against PD-1 and CTLA-4 in
refractory and metastatic solid tumors and non-small cell lung cancer, respectively
(NCT03388632, (345)).
Proof of the potential immunotherapeutic value for IL-15 is abundant and with its
potential synergistic effects with many other types of immune-based therapies it is not
surprising that most studies have focused on its therapeutic effects against cancers.
However, as an endogenous promoter of natural and intrinsic responses by CD8 T
cells and NK cells, it is important to investigate if this homeostatic and inflammatory
cytokine plays important functions during unstimulated intrinsic anti-tumor responses.
Studies of human colorectal tumors highlighted an important role for IL-15 expression
in tumors. Jerome Galon’s group performed genetic analysis of human colorectal
tumors and found that a group of 13 cytokines were differentially expressed.
Importantly, IL-15 was deleted in a subset of tumors and the loss of IL-15 correlated
with increased risk of tumor relapse, decreased patient survival and decreased
proliferation of tumor-infiltrating T and B cells (346). Moreover, studies using IL-15
deficient mice discovered that loss of IL-15 expression in colitis-associated colon
carcinomas leads to increased incidence and tumor burden, decreased overall survival,
and correlates with upregulated expression of inflammatory mediators that promote
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colon cancer progression in tumor tissues (347). Several other preclinical studies
where cancer cells where engineered to express IL-15 showed that IL-15 in the TME
can prevent tumor and metastasis development, control tumor growth and potentiate
NK cell killing of tumor cells (348-354). Accordingly, IL-15 expression in the TME was
shown to augment anti-tumor immunity and taken together these findings pointed to an
important role for endogenous IL-15 as an inflammatory mediator in the TME. While
these findings suggested the importance of TME-derived IL-15, direct evidence as to
how IL-15 production is regulated in tumors, the cellular sources and the mechanisms
by which it enhances anti-tumor immunity was lacking and I aimed to address this gap
in knowledge in this dissertation. These findings will be discussed in Chapters 3 and 4
of this dissertation.
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1.5 Summary
The complex interplay between the immune system and cancer cells usually results
in tumor cells escaping elimination by innate and adaptive lymphocytes and eventual
spread of disease to nearby organs. Tumors are surrounded by stromal cells and
infiltrating immune cells that can promote disease progression and spread of disease.
What is more, tumors have evolved intrinsic and extrinsic mechanisms to curtail immune
responses leading to decreased infiltration of T cells and NK cells in tumors, and increased
infiltration of immunosuppressive cells including Tregs and MDSCs. Although, rejection
and elimination of tumors is rarely achieved naturally or in response to therapies, the
immune system is still capable of mounting strong anti-tumor responses when the
mechanisms of immunosuppression in tumors can be circumvented. This has been
demonstrated with the sustained responses achieved with immune checkpoint inhibitors in
solid tumors like melanomas and with adoptive CAR T cell therapies for leukemias and
lymphomas (355, 356).
Understanding how the cells and inflammatory factors in the TME can be polarized
to promote more robust anti-tumor responses by CD8 T cells and NK cells is crucial for
achieving better and broader responses and positive clinical outcomes, including
increased survival and decreased chances of relapsing, in patients with very aggressive
and hard to treat cancers such as pancreatic, brain and colon cancers and in patients with
disease that has already metastasized to other organs. To this extent, my studies focused
on investigating the roles of locally-produced IL-15 in TME as a promoter of CD8 T cell and
NK cell responses. Based on the results from human colorectal tumors and other
preclinical models of several types of cancers, there was strong evidence pointing to this
inflammatory cytokine as an important part of the inflammatory milieu in the TME. Thus, in
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this dissertation I investigated the hypothesis that IL-15 produced in the TME is an
important promoter of anti-tumor responses by cytotoxic lymphocytes enhancing their
optimal numbers, effector functions and metabolic fitness. To test this hypothesis, I
pursued the following specific aims:
Aim 1. Determine the importance of IL-15 expressed within the tumor for anti-tumor
responses by CD8 T cells and NK cells in melanoma and colon carcinoma tumors.
Aim 2. Investigate the mechanisms by which IL-15 regulates TIL numbers and
induces anti-tumor responses.
Aim 3. Examine if upregulation of IL-15 in tumors, by local IL-15 therapy, promotes
anti-tumor responses in poorly immunogenic melanoma tumors.
To test these aims I used several mouse tumor models including B16 melanomas
and MC38 colon carcinomas. These tumor models were chosen because B16 melanomas
are poorly infiltrated by T cells (357) and can represent the subset of non-T cell inflamed
tumors, and MC38 tumors are more infiltrated and are more similar to T-cell inflamed
tumors (358, 359). This classification of tumors as T-cell inflamed or non-T cell inflamed
tumors has been used to describe subsets of tumors found in patients, especially in
melanoma, that differ in their responses to immune checkpoint blockade and have distinct
gene signatures (360). T-cell inflamed tumors have a gene signature indicative of T cell
infiltration which includes expression of chemokines such as CCL2, CCL3, CCL4, CCL5
and CXCL9 &10 and IFN-I production (9, 361), while non-T cell inflamed tumors lack this
signature. However immunosuppressive cells such as TAMs, TECs, CAFs are still present
in these non-T cell inflamed tumors (19, 361-364). Importantly, non-T cell inflamed tumors
are thought to evade or fail to sustain spontaneous anti-tumor responses likely due to the
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loss of Batf3+ DCs and through activation of tumor intrinsic oncogenic pathways, such as
the Wnt/-catenin pathway leading to exclusion of T cells from the TME and failure to
respond to immunotherapies that boost T cell cytotoxic activities (53, 365). Consequently,
exploring therapeutic avenues to promote spontaneous T cell priming and recruitment of
these cytotoxic lymphocytes, by boosting the recognition of tumors by innate immune cells
in the TME, should be the focus to circumvent the resistance mechanisms to
immunotherapy employed by non-T cell inflamed tumors.
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CHAPTER 2: METHODOLOGY
Mice
C57Bl/6 (WT) and CD45.1+ C57Bl/6 mice were purchased from NCI/Charles River
(Frederick, MD). All transgenic and gene-deficient mice used are on the C57Bl/6
background. IL-15Rfl/fl (251), CD11cCre (366), LysM-Cre (367), and Tmem173-/- mice
(368) were purchased from Jackson Laboratories (Bar Harbor, MN). IL-15R-/- knockout
(RKO) mice (220) were originally generated and obtained by Dr. Averil Ma through Leo
Lefrancois and backcrossed to the C57Bl/6 line. CCR2-DTR Tg mice (369) were
generated by and provided by Dr. Eric G. Pamer (Memorial Sloan Kettering, New York,
NY). IFNAR1-/- mice were provided by Dr. Paul W. Dempsey (Department Of Microbiology
and Molecular Genetics, University of California, Los Angeles and Dr. Tadatsugu
Taniguchi, Department of Immunology, Tokyo University, Japan) to W. Overwijk (Nektar
Therapeutics) and crossed to the C57Bl/6 background (370). IL-15 transcriptional reporter
mice were generated by Dr. Leo Lefrancois (Department of Immunology, University of
Connecticut, Farmington, CT) (280). IL-15 translational reporter mice (IL-15 TE) were
provided by Drs. Pippa Marrack and Ross Kedl (Integrated Department of Immunology,
University of Colorado, Denver, CO) (279). CCR2-RFP reporter mice (371) were originally
obtained from Jackson Laboratories through Dr. Tomasz Zal (Department of Immunology,
UTMDACC) and bred to the IL-15 transcriptional reporter mice to generate GFP+/RFP+
reporter mice. All mice described were maintained under specific pathogen-free conditions
at the institutional animal facility. The animal facility is fully accredited by the Association of
Assessment and Accreditation of Laboratory Animal Care International. All animal
procedures were conducted on mice between 6-10 weeks of age, in accordance with the
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animal care and use protocols (100409934) approved by the Institutional Animal Care and
Use Committee at the UT MD Anderson Cancer Center.
To generate BM chimeras, BM was collected from the tibia and femurs of IL-15R-/(CD45.2) and WT (CD45.2) mice and depleted of T cells as previously described (247) .
WT (CD45.1) recipients were irradiated with 1,000 RADs and injected i.v. with 5 x10 6 BM
cells. BM reconstitution was confirmed 8-12 weeks later by analysis of BM derived cells
(CD45.2+) in the peripheral blood prior to tumor implantation.
Tumor implantation, treatment, and monitoring
B16-F10 melanoma cells (B16), B16-F10 cells expressing OVA (B16-OVA) and
MC-38 murine colon adenocarcinoma tumor cell lines were obtained from W. Overwijk and
maintained in RPMI culture medium containing 10% FBS, 1% Hepes, 1% L-glutamine and
1% Penicillin/Streptomycin (P/S). MCA-205 fibrosarcoma were obtained from Dr. Tomasz
Zal, and maintained in IMDM culture medium containing 5% FBS, 1% P/S and 50μM 2ME. After trypsinizing and washing, 300,000 cells were injected s.c. into the flank of the
indicated mice. Tumor growth was measured every other day using a caliper and tumor
surface area (mm2) was calculated as length X width. Mice were sacrificed at various
times post-implantation or when tumors reached 200mm2. For analysis of naive tumorspecific T cell responses, CD45.1+ OT-I TCR transgenic CD8 T cells (RAG-/-) were
isolated from LNs and spleen, labeled with 2mM CFSE, and adoptively transferred to
CD45.2+ WT recipients.
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Analysis of Cytokine Expression and Lymphocytes
For analysis of sIL-15 complexes, spleens and tumors were weighed prior to being
homogenized in a constant volume of PBS and pelleted by centrifugation. Supernatants
were collected and analyzed for levels of sIL-15 complexes using an ELISA specific for
murine sIL-15 complexes (eBioscience, San Diego, CA) according to manufacturer’s
recommendations. The amount of sIL-15 complexes present in the respective tissue was
normalized to tissue weight and expressed as the amount of sIL-15 complexes/g of tissue.
For analysis of immune cells and IL-15 reporter expression in tumors, tumors were
isolated, digested in RPMI media, 5% FCS and 100 U/ml collagenase, 1mM CaCl2 and
1mM MgCl2 for 30 min at 37°C with stirring and then subjected to a 44-67% Percoll
centrifuge gradient. Cells in the interphase were harvested, washed, and then stained for
flow cytometric analysis. Spleens were homogenized in HBSS containing HEPES, Lglutamine, gentamicin and pen-strep using frosted slides. RBC were lysed with Trisammonium chloride. All cells were filtered through a 70m nitex prior to staining. For flow
cytometric analysis, cells were stained in 1x PBS containing 0.2% BSA and 0.1% NaN3
with appropriately diluted Ab at 4°C for at least 20 min. Ki-67 and Granzyme B staining
were conducted after staining cell surface molecules and permeabilization using the
FoxP3/ Transcription Factor Staining Buffer Set according to manufacturer’s instructions
(eBioscience). For IFN- staining, isolated lymphocytes were stimulated in the presence of
plate-bound CD3Ab for 5 hours in the presence of Golgi Plug (BD Bioscience). IFN-
staining was conducted after staining for cell surface molecules and permeabilization using
Cytofix/Cytoperm buffer according to manufacturer’s instructions (BD Bioscience). The
following mAbs were purchased from BD Biosciences (San Jose, CA), eBiosciences, or
BioLegend: CD45, CD45.1, CD45.2, CD19, CD3, TCRβ, CD11b, CD11c, Ly6G, Ly6C,
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F4/80, CD8, NK1.1, CD44, Ki-67, IFN-, and Granzyme B. Lineage+ cells were identified
as CD19+, TCRβ+, or NK1.1+. Rat IgG2a-APC (Biolegend) was used as an isotype control
for F4/80-APC, while Rat IgG1-PE (BD Biosciences) was used as an isotype control for
IFN--PE and Granzyme B-PE. Flow cytometric data were acquired with a LSRII (BD
Biosciences) or LSR Fortessa (BD Biosciences) and analyzed with Flowjo software version
9.7.6 and 10 (Flowjo LLC, Ashland).
Cell depletions, STING agonist treatments, and IL-15 neutralization
To deplete mice of Ly6G+ cells, mice were treated i.p. with Ly6G mAb (clone 1A8,
400 μg, BioXcell) or Rat IgG (Jackson ImmunoResearch Laboratories) when tumors
became palpable (day 8-9) and 3 days later with Ly6G mAb (100 μg i.p and 50 μg i.t.). To
deplete CCR2+ cells, CCR2-DTR Tg and WT mice were treated with 250 ng of Diphtheria
Toxin (Sigma) every two days starting 4 days post tumor implantation. Efficiency in
depletion of Ly6G+ cells and Ly6C+ monocytes in the respective models were confirmed
by flow cytometry. Levels of sIL-15 complexes in B16 tumors and spleens were analyzed
2-3 days later by ELISA as described. For stimulation of the STING pathway, mice were
administered i.t. c-di-GMP or 2’3’-c-GAMP (Invivogen, San Diego, CA) at the indicated
doses. Neutralizing IL-15 mAb (clone M96) (372) was obtained from Amgen (Thousand
Oaks, CA). For systemic neutralization of IL-15, mice received one treatment (50g, i.p.)
of IL-15 mAb at indicated time after tumor implantation. Mouse IgG2a (Jackson
ImmunoResearch Laboratories) was used as the isotype control. For local neutralization
of IL-15, IL-15 Ab was delivered intratumorally at indicated doses when tumors became
palpable. Efficient neutralization of IL-15 with antibody was confirmed by the absence of
NK cells.
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Metabolic assays, Annexin V and BrdU staining
Tumor homogenates were pulsed with 20 µM 2-NBDG (Cayman Chemical) in 10%
FBS-containing media for 1hr at 37°C. Cells were surface stained and analyzed by flow
cytometry. For Annexin V staining, tumors were dissociated and stained for 30 minutes at
room temperature using the Annexin V staining kit (Invitrogen), according to
manufacturer’s recommendations. For BrdU accumulation and flow cytometry analysis
tumor bearing mice received i.p. injections of BrdU (2 mg; Sigma Aldrich, St. Louis, MO)
every 2 days for 7 days. Tissues were harvested and cell surface stained in 1X PBS
containing 0.2% BSA and 0.1% NaN3 at 4˚C for at least 20 min. Staining for BrdU was
performed using BrdU Flow kit according to manufacturer’s instructions (BD Biosciences
Pharmingen, San Jose, CA). In brief, cells were fixed and permeabilized using BD
cytofix/cytoperm buffer, followed by DNase (30 µg) treatment for 1 hour at 37˚C. Cells
were then stained with anti-BrdU FITC for 20 min at room temperature.
Immune checkpoint inhibition and IL-15 agonists treatment
Anti-CTLA-4 mAb (clone 9H10, from BioXcell) was kindly provided by James Allison
and Michael Curran (MD Anderson Cancer Center, Houston TX). It was administered to
tumor-bearing mice i.p. at an initial dose of 200g/mouse on day 5 post-tumor implantation
and then at a dose of 100g/mouse every three days for a total of 5 treatments. For
intratumoral treatment with rsIL-15c, 50ng of recombinant murine IL-15 (PreproTech) were
combined with 300ng of recombinant IL-15R-Fc (R& D Systems) in PBS and incubated at
37°C for 10 minutes. Mice received intratumoral injections on days 8, 11 and 14. A
polymer-conjugated recombinant IL-15 (NKTR-255) was provided by Nektar Therapeutics
(San Francisco, CA). Mice received intratumoral injections of 60 ng of NKTR-255 on
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indicated days after tumor implantation and treatments were repeated every other day until
tumor regressed or reached 200 mm2.
Statistical Analysis
Statistical differences were determined by a two-tailed Students t test, one-way ANOVA or
Log-rank Test. *, **, ***, **** indicate p<0.05, p<01, p<0.001, and p<0.0001, respectively.
Analyses were performed using GraphPad Prism, version 8 (GraphPad Software, San
Diego, CA) or Microsoft Excel 2016 (Redmond, WA).
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CHAPTER 3: IL-15 IS AN IMPORTANT INFLAMMATORY SIGNAL IN THE TME THAT
ENHANCES ANTI-TUMOR RESPONSES
This work is based upon “IL-15 is a component of the inflammatory milieu in the
tumor microenvironment promoting anti-tumor responses” by Rosa M. Santana Carrero,
Figen Beceren-Braun, Sarai C. Rivas, Shweta M. Hegde, Achintyan Gangadharan, Devin
Plote, Gabriel Pham, Scott M. Anthony and Kimberly S. Schluns. 2019. Proceedings of the
Natural Academy of Sciences USA (PNAS); presented with permission from PNAS.
3.1: Introduction
Patients vary considerably in their responses to cancer therapies. The presence
of tumor-infiltrating T cells strongly correlates with positive clinical outcomes in
melanoma, colon, breast, cervical, and brain cancers (82-85). Specifically, the density,
depth, and functional attributes of cytolytic CD8 T cells are associated with the greatest
clinical outcomes (82). Altogether, these features are a better prognostic indicator than
the tumor-node metastasis classification that is currently used. IL-15 is a cytokine that
preferentially stimulates CD8 T cell and NK cell activation, proliferation, and cytolytic
activity. Not surprisingly, these functional activities of IL-15 translate to enhanced antitumor responses in multiple tumor models (289, 341, 373). As such, systemic treatment
with IL-15 or IL-15 analogs are currently being evaluated as potential cancer
therapeutics. In addition to the ability of IL-15 to act systemically to promote anti-tumor
responses, there is evidence that IL-15 expression within the tumor microenvironment
(TME) is crucial for optimal anti-tumor responses (346, 374). Jerome Galon’s group
showed that loss of IL-15 expression within colorectal tumors correlated with lower T
cell density, decreased T cell proliferation, higher risk of relapse, and decreased
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survival (346). While these studies suggest IL-15 produced within the TME is important
for effective anti-tumor responses by CD8 T cells, the mechanisms regulating IL-15
within tumors are unknown.
As little was known of the significance of locally produced IL-15 in tumors in
adaptive anti-tumor immune responses this study focused on investigating if and how
IL-15 expression was regulated by factors such as other inflammatory mediators and
increased tumor growth and development. Several models of IL-15 expression were
evaluated to investigate specific cellular sources of IL-15 since IL-15 protein expression
had been difficult to quantify due to the stringent regulation of IL-15 production at the
transcriptional, translational and post-translational levels. Furthermore, while
transpresentation of IL-15 is known to mediate IL-15 effects during homeostatic
conditions (235, 246, 249), transient increases in IL-15 levels can be observed by the
generation of sIL-15 complexes in response to many types of innate immune cell
stimulation (238, 272). Moreover, as therapeutic sIL-15 complexes are 50-100X times
more potent than rhIL-15 in promoting CD8 T cell and NK cell proliferation in vivo, it
was important to examine how the production of these complexes in the TME could
affect TIL responses.
In this chapter I will demonstrate that IL-15 is expressed in the TME as sIL-15
complexes and regulates TIL numbers. sIL-15 complexes are abundant in early tumors
but low in established tumors, even though IL-15 expressing cells are abundant in
established tumors. Nonetheless, sIL-15 complexes can be upregulated by stimulating
the inflammatory STING pathway. More importantly, the induction of IL-15 expression
by locally delivered inflammatory signals was critical for mediating anti-tumor
responses.
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3.2 Results
3.2.1: IL-15 expression and regulation in the tumor microenvironment
Inflammatory mediators, including cytokines, are initially produced in the TME to
promote anti-tumor responses, however as tumors develop this microenvironment
gradually becomes immunosuppressive and hostile to immune cells (9, 375). Our
group’s findings that sIL-15 complexes are produced in response to numerous forms of
immune stimulation compelled us to investigate whether sIL-15 complexes are
produced in the TME (199). To determine if sIL-15 complexes are produced in B16
tumors, B16 tumors (B16-F10) were established in WT (wildtype) C57Bl/6 mice,
removed along with spleens, measured in size and weight (tumor weight between 20150mg), dissociated, and suspended in PBS. Supernatants generated after pelleting
cells were analyzed for sIL-15 complexes using ELISA. We found that sIL-15
complexes were present at relatively high levels in small tumors and at lower levels in
larger tumors (Fig. 4A). In analysis of MC-38 and MCA-205 tumors, sIL-15 complexes
are also produced during early tumor growth demonstrating that production of sIL-15
complexes in tumors is not unique to B16 melanoma (Fig. 4B & 4C). Similar levels of
sIL-15 complexes were found in B16-ovalbumin (OVA) tumors as B16-F10 tumors (Fig.
4D). As such, the B16-OVA line was used for in vivo experiments from here on as it
allows the analysis of tumor-specific CD8 T cell responses. We also examined the
levels of sIL-15 complexes in B16 tumors at different times post-implantation and found
that sIL-15 complexes are higher at earlier stages of tumor growth and their levels are
reduced with tumor growth (Fig. 4E). Additionally, in both B16 and MC-38 tumors, the
higher levels of sIL-15 complexes occur in the earliest tumors prior to the infiltration of
CD8 T cells and decline thereafter prior to the decline in numbers of CD8 tumor66

infiltrating lymphocytes (TILs) that occurs with tumor growth (Fig. 4F & 4G). These
findings suggest IL-15 positively regulates CD8 T cell numbers in the TME.

Figure 4. sIL-15 complexes are produced in the tumor microenvironment. A) B16F10 tumor cells were injected (0.3x106 cells, s.c.) into WT mice. Tumors were
dissociated and supernatants were analyzed for sIL-15 complexes using ELISA.
Levels of sIL-15 complexes in B16-F10 tumors of different masses isolated at the same
time post-implantation. B, C) MCA-205 or MC-38 tumors were isolated from WT mice
(MCA between 5-10 days/MC-38-between 10 and 18 days post-implantation) and
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levels of sIL-15 complexes in tumors were analyzed by ELISA. D) Levels of sIL-15
complexes in B16-F10 and B16-OVA implanted at the same time and isolated 10 days
post-tumor implantation. Average tumor weight (mg): B16-F10= 58± 4; B16-OVA=
41±17. E) Levels of sIL-15 complexes in B16-F10 tumors isolated at 10, 14, and 17
days post tumor implantation. n=5 mice/group. F, G) Levels of sIL-15 complexes (light
blue bar, left axis) and total CD8 T cells/tumor (purple bars, right axis) in B16-F10 and
MC-38 tumors, tumors grouped by tumor size. Error bars represent SEM, * p<0.05,
**p<0.01 by Student’s T-test. Data for Figure 4 A, B, C and E generated by and used
with the permission of Sarai C. Rivas, Figen Beceren-Braun, Scott M. Anthony and
Gabriel Pham.
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Since IFN-I expressed in the TME are important for spontaneous anti-tumor
responses (9) and we have previously demonstrated IFN-I are potent inducers of sIL15 complexes in vivo (199), we asked if IFN-I signaling is important for the production
of sIL-15 complexes in the TME. In B16 tumors transplanted into IFNAR-/- mice, sIL15 complexes were decreased in the early tumors compared to those in WT mice (Fig.
5A) indicating IFN-I are important for production of sIL-15 complexes in the TME. Since
IFN-I can be induced by the STING pathway, we asked if the STING pathway was
important for endogenous production of sIL-15 complexes. B16 tumors implanted into
TMEM173-/- mice showed similar levels of sIL-15 complexes as WT mice (Fig. 5B)
suggesting this IFN-I response was not dependent on the STING pathway.
Furthermore, total numbers of CD8 T cells, CD4 T cells, and NK cells among TILs were
decreased in B16 tumors implanted into IFNAR-/- mice compared to WT mice (Fig.
5C). The increase in the CD4:CD8 T cell ratio in tumors of IFNAR-/- mice reflects the
more dramatic loss in CD8 T cells, which is consistent with the loss of IL-15 as IL-15
preferentially stimulates CD8 T cells over CD4 T cells (259). Overall, IL-15 is expressed
as sIL-15 complexes in the TME in an IFN-I-dependent manner that also regulates the
number of CD8 and NK TILs.

69

Figure 5. Regulation of sIL-15 complexes production in tumors and TIL
numbers by IFN-I. A) B16-OVA cells were injected (0.3x106 cells, s.c.) into WT or
IFNAR-/-mice; levels of sIL-15 complexes in tissues were analyzed 10 days postimplantation; n=4-8 mice/group. Tumor masses range from 10-55 mg (WT ave=34.7 ±
17.6, KO ave=41.1±16.6). B) Levels of sIL-15 complexes in B16-OVA tumors implanted
in TMEM173-/- mice 9 days tumor post-implantation. n=5-8 mice/group. Average tumor
weights were WT 21± 7.1; KO=19.8±3.3. C) The numbers of CD8 T cells, CD4 T cells,
and NK cells in B16-OVA tumors implanted into WT or IFNAR-/- mice were analyzed by
flow cytometry and normalized to tumor weight. One representative experiment of three
performed is shown (n=5 mice/group). Error bars represent SEM, * p<0.05, **p<0.01 by
Student’s T-test. Data for Figure 5 A&B were generated by and used with permission of
Sarai C. Rivas and Scott M. Anthony.
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3.2.2 Cellular sources of sIL-15/ IL-15R complexes
To address the extent to which sIL-15 complexes were derived from the tumor
stroma, levels of sIL-15 complexes were measured in tumors implanted into WT and IL15R-/- mice. sIL-15 complexes were not detected in B16 tumors implanted into IL15R-/- mice (Fig. 6A) indicating the sIL-15 complexes were derived from the tumor
stroma and not the tumor cells. However, when either MC-38 or MCA-205 tumor cells
were implanted in IL-15R-/- mice, sIL-15 complexes in the interstitial fluid of these
tumors were still abundant, suggesting the tumor cells themselves were producing sIL15 complexes (Fig. 6B). This was confirmed in analysis of culture supernatants
obtained from these tumor cell lines (Fig. 6C). Tumor cell lines, such as BP-1
Melanoma cells, MB49 bladder carcinoma, and 4T1 mammary tumor cells also
produced sIL-15 complexes while T3M4 pancreatic cancer, A20 Lymphoma, and CT26
colon carcinomas cell lines did not produce detectable levels of sIL-15 complexes (Fig.
6D & E). Thus, the ability of tumor cell lines to produce sIL-15 complexes is variable
but is not necessarily dictated by the tissue of origin. Therefore, we have identified
different scenarios of sIL-15 complex production: one where sIL-15 complexes are
exclusively derived from the TME (i.e. B16) and the other where sIL-15 complexes can
come from both the tumor and the tumor stroma (i.e. MCA-205, MC-38).

71

Figure 6. Stromal and tumor cells are sources of sIL-15 complexes in the tumor
microenvironment. Tumor cells were injected (0.3x106 cells, s.c.) into WT or IL-15Rα/- mice. Tumors and spleens were dissociated and supernatants were analyzed for sIL15 complexes using ELISA. A) Levels of sIL-15 complexes in B16-OVA tumors
implanted in WT and IL-15Rα-/- mice; n=2-3 mice/group. Error bars represent SD. B)
Levels of sIL-15 complexes in MCA-205 tumors (day 9-11) and MC-38 tumors (day
between 9-14) isolated from WT and IL-15Rα-/- mice. Average tumor mass of MCA205 tumors were WT =21.6 ±17, Rko =24.8±6; average tumor mass of MC-38 tumors
WT =32.8±8.3, Rko =28.4±9.7. C) Levels of sIL-15 complexes present in tumor cell
culture supernatants. D) The following tumor cell lines: BP-1 Melanoma cells, T3M4
pancreatic cancer, A20 Lymphoma, CT26 colon carcinomas cell lines, MB49 bladder
carcinoma and 4T1 mammary tumor cells were grown to almost confluent levels in
complete media and culture supernatants were collected. Culture supernatants and the
respective complete media were analyzed for sIL-15/IL-15R complexes by ELISA (3
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wells/cell line), *p<0.05. E) In a different experiment, levels of sIL-15 complexes in
tumor culture supernatants were measured and normalized to the number of cells
recovered. Error bars represent SEM. * p<0.05, with Student’s T-test. Data for this
figure were generated by and used in this dissertation with permission from Figen
Beceren-Braun, Sarai C. Rivas, Shweta M. Hegde and Achintyan Gangadharan.
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Since we demonstrated that sIL-15 complexes present in the B16 tumors are
derived exclusively from the tumor stroma, we chose to use the B16 model to further
investigate the non-tumor derived sources of sIL-15 complexes in the TME. We utilized
various IL-15R conditional knockout mouse models: IL-15R floxed mice (IL-15Rfl/fl)
crossed to CD11c-Cre Tg mice or LysM-Cre Tg mice to delete IL-15R primarily in DCs
and phagocytic cells (macrophage and neutrophils), respectively as previously
described (251). Loss of IL-15 expression from either DCs (Fig. 7A) or phagocytic cells
(Fig. 7B) led to a significant reduction in the levels of sIL-15 complexes in B16 tumors,
suggesting both cell types are contributing to baseline sIL-15 complex levels in the
TME. To examine the contribution of monocytes, B16 cells were implanted into CCR2DTR Tg+ and Tg- littermates and treated with diphtheria toxin (DT) (200 ng, i.p. every 2
days) to deplete CCR2+ myeloid cells. Treatment with DT consistently decreased the
levels of sIL-15 complexes in B16 tumors implanted into DTR-Tg+ mice compared to
the tumors in DT-treated Tg- mice (Fig. 7C); however, these differences did not reach
statistical significance (p<0.1). To examine the specific contribution from tumor
associated neutrophils or granulocytic myeloid-derived suppressive cells (MDSC), sIL15 complexes were analyzed in tumors from mice treated with Ly6G depleting Ab. This
treatment had no effect on levels of sIL-15 complexes suggesting neutrophils/MDSCs
are not a significant source of sIL-15 complexes in the TME (Fig. 7D). In no model
examined, were sIL-15 complexes reduced by more than 50% indicating that there are
multiple myeloid sources of sIL-15 complexes in the TME, including CD11c+, LysM+
phagocytic cells, and monocytic cells.
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Figure 7. Multiple myeloid cell subsets and non-hematopoietic cells generate sIL15 complexes in the stromal compartment of the TME. A,B) Levels of sIL-15
complexes in spleens and B16-OVA tumors isolated from control IL-15Rfl/fl (blue),
CD11c-Cre+/+ x IL-15Rfl/fl (red), and LysM-Cre+/+ x IL-15Rfl/fl (red) mice 10 days
tumor post-implantation (n=3-5 mice/group), one representative experiment of three is
shown. C) B16-OVA tumors were implanted in CCR2-DTR-Tg- (blue) and CCR2-DTRTg+ (red) mice. Beginning 7 days post-implantation, mice were treated i.p. with either
PBS or DT every two days. Tumors and spleens were isolated 12-13 days postimplantation. Tumors ranging between 50-100 mg were analyzed and average tumor
mass was not significantly different between groups (n=3 tumors/group, n=4-6
spleens/group). D) B16-OVA tumors were implanted in WT mice. When tumors
became palpable (day 8-9), mice were treated either with Ly6G Ab (clone 1A8, 400
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μg, i.p.) or Rat IgG and 3 days later with Ly6G Ab (100 μg, i.p. plus 50 μg i.t.). Levels
of sIL-15 complexes in B16 tumors and spleens were analyzed 2-3 days later. n=5
mice/group. E) Levels of sIL-15 complexes in B16-OVA tumors and spleens isolated
from IL-15R-/- BM chimeras (IL-15R-/- BM→ WT recipients) and WT control BM
chimeras (WT BM→ WT recipients) 2 weeks after implantation, n=4-5 mice/group.
Error bars represent SEM. * p<0.05 with Student’s T-test. Data for this figure were
generated by and used in this dissertation with permission from Figen Beceren-Braun,
Sarai C. Rivas and Devin Plote.
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We also examined the contribution of non-hematopoietic cells as sources of sIL15 complexes using bone marrow (BM) chimeras. IL-15R-/- BM chimeras (IL-15R-/BM→ WT recipients) and WT control BM chimeras (WT BM→ WT recipients) were
generated and reconstitution of the hematopoietic compartment was confirmed ~12
weeks later followed by s.c. implantation of B16 tumor cells. Tumors and spleens were
analyzed for sIL-15 complexes two weeks later. B16 tumors isolated from IL-15R-/BM chimeras expressed lower levels of sIL-15 complexes than WT BM chimeras
(p<0.1) (Fig. 7E) indicating non-hematopoietic cells may be an additional source of sIL15 complexes in the TME. Overall, our analyses demonstrate that there are multiple
sources of sIL-15 complexes in the TME including multiple myeloid cells, nonhematopoietic cells, and in some instances the tumor cells themselves.

3.2.3 The tumor microenvironment is abundant in IL-15-expressing myeloid cells,
composed predominately of CD11b+Ly6ChiLy6G- cells.
Our next objective was to more specifically identify the cells expressing IL-15
within the TME and determine how IL-15 expression in the TME differs from that in the
spleen. To address this, B16 tumor cells were implanted into WT, IL-15 transcriptional
reporter, or IL-15 translational reporter mice, allowed to grow, and tissues were isolated
for flow cytometric analysis of GFP+ cells. Between 12-18 days post-implantation, GFP
expression was compared in dissociated tumors and splenocytes. Among splenocytes,
the majority of TCRαβ CD19 NK1.1 (lineage)- cells are GFP+ (~75%) and consist of
CD11chi DCs, neutrophils (CD11b+Ly6G+), monocytes (CD11b+Ly6Chi), and
macrophages (CD11b+Ly6C-/loLy6G-), similar to that described in previous studies
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(376) (Fig. 8A). Similar to spleen, most myeloid cells in the tumor are GFP+(80-90%);
however, the composition of the GFP+ cells was different than that in the spleen. In
B16 tumors, a larger portion of CD45+lineage- cells were CD11bhi CD11clo/int than in
the spleen (Fig. 8A). Additionally, while GFP+ CD11chi cells and other CD11blo cells
are found in the spleen, the proportion of CD11chi cells among GFP+ populations in
the tumor are low in comparison to that observed in the spleen (Fig. 8A). Among the
GFP+CD11b+ cells in B16 tumors, there are three main populations: Ly6ChiLy6G(monocytic), Ly6C+Ly6G+ (neutrophils or granulocytic MDSC), and Ly6C-/loLy6G- cells
(Fig. 8A). Unlike the spleen, the GFP+CD11b+ cells in B16 tumors were composed
predominantly of Ly6ChiLy6G- cells while Ly6C+Ly6G+ cells were minimally
represented (Fig. 8A). Similar analyses were also conducted with the MC-38 colon
carcinoma cell line and MCA-205 fibrosarcoma implanted into IL-15 reporter mice. In
general, the composition of GFP+ cells in MCA-205 and MC-38 tumors was similar to
that observed in B16 tumors, except that MC-38 tumors harbored a higher percentage
of CD11chiGFP+ cells and slightly less CD11b+Ly6C-/loLy6G- cells (Fig. 8B & C).
MCA-205 tumors harbored slightly more CD11b+Ly6C-/loLy6G- cells among GFP+
cells compared to B16 and MC-38 tumors but this was not statistical significant (Fig.
8B). The composition of GFP+ cells between the two IL-15 reporter mouse lines was
equivalent (Fig. 8D). Overall, across multiple implantable tumor cell lines, tumor
myeloid cells expressing IL-15, composed predominantly of CD11b+Ly6ChiLy6G- cells,
are abundant in established tumors.
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Figure 8. CD11b+Ly6Chi Ly6G- cells are the major subset expressing IL-15 in
TME. (A) Flow cytometric analysis of IL-15-GFP expressing myeloid subsets in spleens
and B16-OVA tumors (200-250 mg) isolated from WT (left panel) and IL-15
translational-GFP reporter (right panel) mice 14 days post-implantation. Spleens and
tumors from WT mice were used to set the gate for GFP+ cells. Expression of CD45+
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and Lineage (TCR-β, CD19, NK1.1) negative cells were used to discriminate myeloid
cell populations. Myeloid cells were then gated on GFP+ cells and the composition of
GFP+ cells was examined by CD11c, CD11b, Ly6G and Ly6C expression.
Representative data from 1 of 6 independent experiments are shown. (B) Composition
of IL-15-GFP expressing cells among CD45+lineage- cells present in B16-OVA, MCA205 and MC-38 tumors isolated from IL-15 reporter mice. Tumors analyzed ranged
from 35-100mm2. Bars show mean ± SD from n = 7-10 mice per group. * represents a
significant difference in frequency of CD11chi cells compared to B16-OVA and MCA205 tumors. C) Flow cytometric plots showing cells in spleens and MCA and MC-38
tumors isolated at the same time from IL-15 translational reporter mice after gating on
CD45+, lineage (TCR-β, CD19, NK1.1) negative, and GFP+ cells. Ly6C and Ly6G
expression was examined in GFP+ CD11b+cells. D) GFP/IL-15 expression in IL-15
translational and transcriptional reporter mice. Flow cytometric plots showing
composition of GFP+ myeloid subsets in similar size MCA tumors isolated from IL-15
translational and transcriptional reporter mice. Data for this figure were generated by
and used in this dissertation with permission from Figen Beceren-Braun.

80

To further define these myeloid subsets, the expression of CCR2, which is
associated with inflammatory monocytes (377), was examined in myeloid cells in B16
tumors implanted into translational IL-15-GFP/CCR2-RFP double reporter mice. Among
the GFP+CD11b+ cells in the tumors, the Ly6Chi Ly6G- cells expressed high levels of
CCR2 reporter, the Ly6C-/loLy6G-cells were predominantly CCR2+, while the
Ly6C+Ly6G+ cells were uniformly CCR2- (Fig. 9A). In addition, we examined F4/80
expression by the GFP+CD11b+ populations in tumors and found that the Ly6C/loLy6G- cells expressed higher levels of F4/80 than the other CD11b+ subsets
implicating these cells as part of the macrophage lineage (Fig. 9B & C). Unlike in the
spleen where macrophages are F4/80hi CD11bint cells, an analogous population was
not observed in the TME but instead, an F4/80loCD11bhi population was observed
(Fig. 9D).
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Figure 9. IL-15 reporter expression is increased in tumor myeloid cells over
similar myeloid populations in the spleen. A) CCR2 reporter expression in indicated
cells isolated from B16-OVA tumors implanted into either CCR2-RFP+/IL-15
transcriptional GFP+ reporter or CCR2-RFP-/IL-15- transcriptional GFP+ reporter. (B)
F4/80 expression on indicated populations after gating on GFP+CD11b+ cells in B16
tumors isolated from IL-15-transcriptional GFP reporter mice. C&D) Tumor cells were
implanted s.c. into IL-15 reporter mice. Tumors and spleens were isolated and stained
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as described. C) Panels show tumor and spleen cells stained with F4/80-APC and Rat
IgG2a-APC after gating on CD45+ lineage- cells. D) Histograms show staining of
F4/80-APC and Rat IgG2a-APC after gating on CD45+lineageneg, GFP+ CD11b+ cells
in spleens and B16 tumors implanted into IL-15 translational reporter mice. (E) The
relative IL-15-GFP reporter expression levels among analogous cells in spleen and
tumors. GFP expression by the specific CD45+lineage- CD11b+ cell populations was
calculated by dividing the MFI of the indicated population isolated from the tumor over
the MFI of the analogous population from the spleen of the same mouse. n=7-10 mice
per group, error bars represent SEM. * p<0.05, **p<0.01, ***p<0.001 with One-way
ANOVA. Data for this figure were generated by and used in this dissertation with
permission from Figen Beceren-Braun.
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To address whether the IL-15 expression is different in specific myeloid cells in
tumors compared to the spleen, we gated on specific myeloid populations and
compared the GFP expression between the spleen and the tumor within the same
mice. In the B16 tumors, GFP expression was increased in the CD11b+Ly6ChiLy6Gcompared to the spleen (Fig. 9E). GFP expression by CD11chi cells,
CD11b+Ly6ChiLy6G- and Ly6C-/loLy6G- cells was also increased in MCA-205 tumors
compared to spleen but decreased in the Ly6C+Ly6G+ population (Fig. 9E). In
contrast, in MC-38 tumors, only the CD11chi cells showed increased GFP expression
relative to that in the spleen (Fig. 9E). Overall, these findings indicate that IL-15
expression is altered among myeloid cells within the TME depending on the myeloid
cell expressing IL-15 and the tumor type.
Since IL-15R is required for expression of cell surface IL-15 complexes and
soluble IL-15 complexes (235, 240), cell surface IL-15R expression by tumor myeloid
cells was examined. All myeloid cell subsets expressed surface IL-15R with the
CD11b+Ly6Chi cells expressing the highest levels (Fig. 10A). In analysis of IL-15R at
different stages of tumor growth, levels of IL-15R by the three major myeloid subsets
did not significantly change between day 9 and day 14 tumors (Fig. 10B). These data
suggest that tumor myeloid cells are capable of both transpresenting IL-15 and
producing sIL-15 complexes.
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Figure 10. IL-15R expression by tumor myeloid cells is stable in early and
established tumors. B16 tumor cells were implanted s.c. into WT and IL-15R-/(Rko) mice 9 and 14 days prior to analysis to allow simultaneous analysis of IL-15R of
two time points. Tumors were isolated, incubated with BD mouse Fc block, and stained
for IL-15R using anti-mouse IL-15R-biotin (R&D Systems) followed by StreptavidinAPC (Jackson ImmunoResearch). A) Histograms show representative staining for IL15R after gating on CD45+ lineageneg CD11b+ cells isolated from tumors in WT
(grey filled) and IL-15R-/- (open histogram) mice. B) Graph shows average MFI of IL15R staining from indicated tumor myeloid cells from IL-15R-/- mice (white bars) and
from WT mice 9 days (light grey bars) and 14 days (dark grey bars) post-tumor
implantation. N=3-5 mice/group. Data for this figure were generated by and used in this
dissertation with permission from Figen Beceren-Braun.
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3.2.4 Local IL-15 in tumors regulates TIL numbers
To directly examine the role of IL-15 in regulating TIL numbers, established
palpable B16 tumors in WT mice were treated intratumorally with neutralizing IL-15 Ab
or control Ig. Blocking IL-15 activity in the tumor led to a significant decrease in the total
number of CD8 T cells and NK cells in the tumors (p<0.001) but did not significantly
affect the total numbers of CD4 T cells (Fig. 11A). Decreases in TIL numbers were also
observed with IL-15 blockade of MC-38 tumors (Fig. 11B). To determine if endogenous
IL-15 regulates proliferation of TILs, Ki-67 expression was examined in TILs in B16
tumors of mice treated with neutralizing IL-15 Ab. Ki-67 expression in CD8, CD4, or
NK1.1+ TILs was similar with IL-15 neutralization and control Ig treatment (Fig. 11C)
suggesting IL-15 regulates TIL numbers independent of proliferation, possibly by
promoting infiltration. TILs were also examined phenotypically and found to have
similar levels of Tim-3+ and PD-1+Tim3+ among both groups (Fig. 11D). Surprisingly,
IL-15 blockade did not affect B16 or MC-38 tumor growth (Fig. 11E & F) suggesting the
amount of IL-15 present in the TME is sufficient to regulate TILs but is not sufficient to
break tolerance against the tumor.
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Figure 11. IL-15 neutralization in TME leads to decreased TIL numbers. A) B16OVA tumors implanted into WT mice were treated intratumorally with IL-15Ab (50 g)
or Rat IgG 9 days after tumor implantation. Tumor lymphocytes were analyzed three
days later by flow cytometry and total cell numbers were normalized to tumor weight. B)
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MC-38 tumors implanted into WT mice were treated intratumorally with IL-15Ab (50
g) 8 days post implantation. One week later, tumor lymphocytes were analyzed by
flow cytometry and total cell numbers were normalized to tumor weight. C) Frequency
of Ki67+ cells among indicated TILs isolated from B16-OVA tumors treated with IL-15
Ab or IgG. D) Frequency of TIM3+ and TIM3+PD-1+ cells among CD8 TILs isolated
from B16-OVA tumors treated with IL-15 Ab or IgG. E, F) Tumor growth of B16-OVA
and MC-38 tumors in WT mice treated with intratumoral IL-15 Ab or PBS 8 days post
B16 tumor implantation or 14 and 22 days post-MC-38 tumor implantation. n= 5
mice/group. Error bars represent SEM, *p<0.05, **p<0.01 by Student’s T-test.
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As local IL-15 blockade regulated the numbers of CD8 TILs in tumors (Fig. 11A
&B) we next investigated several mechanisms by which IL-15 could influence the total
numbers of CD8 TILs these in tumors. The more studied and established roles for IL-15
during steady-state conditions involve its functions in maintaining homeostatic levels of
proliferation of CD8 T cells and serving as a survival signal for CD8 T cells during the
contraction phase of an immune response (226, 378-380). In terms of enhancing
proliferation we showed that Ki67 expression by CD4, CD8 and NK TILs was not
affected by IL-15 neutralization in tumors (Fig. 11C). However, Ki67 expression by cells
only represents the proliferation during a very short time period, thus we measured
BrdU incorporation as an indicator of proliferation over a longer time period. To this
extent, mice bearing established B16-OVA tumors received i.p. injections of BrdU and
tumors were treated with i.t. IL-15 ab and harvested for flow cytometry analysis.
Similar to the results for Ki67 expression, IL-15 blockade in tumors did not significantly
impact the levels of BrdU incorporation by CD4 and CD8 TILs in tumors (Fig. 12A).
These results point to other mechanisms involved in the IL-15 regulation of TIL
numbers in tumors.
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Figure 12. IL-15 blockade does not significantly affect TIL proliferation,
survival and glucose metabolism in melanoma tumors. A) B16-OVA tumors were
implanted into WT mice and treated with 50g of IL-15 Ab i.t. or Rat IgG on day 7
post-implantation. Mice received i.p. injection of BrdU on days 4, 6, 8 and 10 after
tumor implantation. On day 13 post-implantation tumors were harvested for flow
cytometry analysis. Left panels- Flow cytometry plots of BrdU+ CD4 and CD8 TILs.
Right panels- frequency of BrdU+ cells among CD4 and CD8 TILs. B) B16-OVA tumors
were implanted into WT mice and treated with 20g of IL-15 Ab i.t. or Rat IgG on day
8 post-implantation. On day 11 post-implantation tumors were harvested for flow
cytometry analysis. Flow cytometry plots show frequency of Annexin V+ cells among
CD4 and CD8 TILs. C) B16-OVA tumors were implanted into WT mice and treated with
20g of IL-15 Ab i.t. or Rat IgG on day 12 post-implantation. On day 14 post90

implantation tumors were harvested and incubated with 20uM solution of 2-NBDG, a
fluorescent glucose analog. Graph represents average 2-NBDG fluorescence in CD4,
CD8 and NK TILs. D) B16-OVA tumors were implanted into WT mice and treated with
20g of IL-15 Ab i.t. or Rat IgG on day 10 post-implantation. On day 12 postimplantation tumors were harvested for flow cytometry analysis. Graphs show average
frequency of IFN- + cells among CD8 TILs. n=5 mice/group. Error bars indicate SEM.
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The next mechanism we investigated was changes in survival. To examine if IL15 influences survival of TILs we treated established B16-OVA tumors with i.t -IL-15 Ab
and analyzed of expression of apoptotic marker Annexin V in CD4 and CD8 TILs.
Annexin V expression was similar in TILs from IL-15 depleted tumors and control treated
tumors (Fig. 12B). While IL-15 depletion from the TME did not induce changes in
apoptotic markers, IL-15 has been shown to promote survival of CD8 T cell and NK cells
by inducing the expression of anti-apoptotic proteins including BCL-2, BCL-XL, Mcl-1
and downregulating the expression of pro-apoptotic proteins including Bim (225-227,
381, 382). Hence, it would be important to look at the expression of these anti-apoptotic
and pro-apoptotic molecules in more detail in future experiments.
Other aspects that could affect the survival of TILs could be decreased metabolic
functions. Recently, studies focusing on T cell metabolism have shed light on the
metabolic reprogramming that occurs during normal T cell development and under
inflammatory conditions (383, 384). During homeostatic conditions naïve T cells rely
mostly on oxidative phosphorylation (OXPHOS) and catabolic metabolic pathways, like
fatty acid oxidation (FAO) (385). Once these cells become activated they must undergo
a metabolic switch, using the glycolytic pathway to proliferate and exert their effector
functions (386). Memory T cells, on the other hand, rely on the use of FAO and OXPHOS
during homeostatic proliferation (387). Although IL-15 has clearly been shown to
enhance proliferation, survival and cytotoxicity of effector CD8 T cells, very few studies
have investigated the ability of IL-15 to promote their metabolic functions (388). These
studies showed that in vitro stimulation of CD8 T cells with IL-15 promotes mitochondrial
biogenesis to generate memory-like CD8 T cells that have increased spare respiratory
capacity (388). To my knowledge, to date no in vivo studies had been performed to define
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if IL-15 also induces these changes on CD8 T cells in the immunosuppressive TME.
Therefore, we investigated if IL-15 neutralization in the TME could affect glucose
metabolism in TILs from B16-OVA tumors treated with an IL-15 blocking antibody. No
significant difference in uptake of a fluorescent glucose analog, 2-NBDG, was detected
in CD4, CD8 or NK TILs from tumors depleted of IL-15 and control treated tumors (Fig.
12C). Lastly, since IL-15 can enhance effector functions of CD8 T cells, we looked at
expression of effector proteins, specifically IFN-, by CD8 TILs in tumors depleted of IL15. We did not detect significant differences in the frequency of IFN-+ cells among CD8
TILs between treatment groups (Fig. 12D). Consequently, these results combined with
the lack of overt changes in apoptotic and proliferation markers in TILs from tumors
where IL-15 was neutralized, suggest that the decreased numbers of CD8 TILs observed
with IL-15 blockade could likely be due to regulation of trafficking and infiltration of these
lymphocytes into tumors. Investigating if IL-15 produced in the TME regulates TIL
numbers by promoting the trafficking and infiltration of these cells into tumors was of
particular interest for me and due to time constraints and difficulties establishing an
adequate model for these experiments I was not able to fully investigate this mechanism.
Future experiments could be performed looking at direct and indirect mechanisms by
which IL-15 could regulate the infiltration of TILs into tumors. Some possible mechanisms
that could be studied are increases in the expression of chemokines and chemokine
receptors by tumor infiltrating myeloid cells and TILs, respectively.
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3.2.5 IL-15 expression can be upregulated in tumors by activating the STING pathway
Although IL-15 reporter+ cells are numerous in established tumors (Fig. 8A),
production of sIL-15 complexes is significantly reduced in the latter (Fig. 4A).
Therefore, we sought to determine if administrating exogenous STING agonists was
capable of upregulating production of sIL-15 complexes in the TME. Despite STING
signaling not being involved in regulation of sIL-15 complexes in early tumor
development, intratumoral (i.t.) injection of the STING agonist, c-di-GMP (25 g) in
large tumors (range 170-260mg) led to an impressive upregulation of sIL-15 complexes
in the tumor (Fig. 13A). Importantly, these data demonstrate the IL-15 expressing cells
present in the TME are capable of producing sIL-15 complexes in the tumor at this later
stage of development. To address which cell types respond to STING activation by
increasing IL-15 expression, B16 tumors established in IL-15 translational reporter mice
were treated i.t. with c-di-GMP, and GFP expression by myeloid cells in the tumor was
examined 24 hours later. In response to STING pathway activation in the TME, we
observed significant increases in GFP expression on the CD11chi, CD11b+Ly6Chi, and
CD11b+Ly6C-/loLy6G- tumor-infiltrating myeloid cell subsets compared to PBS
treatment (Fig. 13B & C). We also wanted to address whether stimulation of the STING
pathway is capable of upregulating sIL-15 complexes directly in tumor cells. Hence,
B16, MCA-205, and MC-38 tumor cells were treated with STING agonist in vitro. As
shown earlier, sIL-15 complexes were not produced by either B16-OVA or B16-F10
tumor cells, even after treatment with STING agonists (Fig. 13D). In contrast, STING
activation increased production of sIL-15 complexes in the tumor cell lines with
baseline detectable sIL-15 complexes, including MCA-205 and MC-38 cells (Fig. 13D)
indicating that in these tumor models, both myeloid cells and tumor cells are capable of
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responding to STING agonists. These results demonstrate that intratumoral activation
of the STING pathway upregulates the translation of IL-15 and the production of sIL-15
complexes in tumors, even at later stages of tumor development.
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Figure 13. Stimulation of the STING Pathway upregulates sIL-15 complexes in
tumors. A) STING agonist, c-di-GMP (25g) or PBS was injected i.t. into large, wellestablished B16-OVA tumors and levels of sIL-15 complexes within tumors were
analyzed 1 day later. Average tumor mass was 259 mg±53 and 173 mg±59 in
untreated and c-di-GMP treated tumors respectively. B) IL-15 reporter expression in
B16-OVA tumors 24 hours after i.t. 2’3’-c-GAMP (25g) or PBS. Histograms show the
GFP levels on indicated cell populations in B16-OVA tumors treated with i.t. 2’3’-cGAMP (purple histogram) or PBS (blue histogram) after gating on CD45+lineageCD11b+ cells. Tumors were treated 14 days after implantation into IL-15 translational
reporter mice. C) Graphs represent the averaged GFP levels of the respective
CD11b+ populations isolated from 2’3’-c-GAMP or PBS-treated tumors in IL-15
translational reporter mice. n= 3 mice/group. D) Sub-confluent B16-OVA, B16-F10,
MCA-205, and MC-38 cells were either left untreated or treated with c-di-GMP (6.6
g/ml) and 48 hours later culture supernatants were analyzed for levels of sIL-15
complexes and normalized to the number of cells recovered. n=3 wells per group. Error
bars represent SEM, *p<0.05, **p<0.01 with Student’s T-test.
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3.2.6 Upregulation of IL-15 in the tumor enhances CD8 T cell responses and promotes
anti-tumor immunity
STING agonists have been shown to enhance anti-tumor responses when given
intratumorally (173, 180, 186, 189, 195). As such, we asked whether tumor specific
CD8 T cell responses were increased by the STING agonist treatment. To examine
this, naïve OVA-specific TCR Transgenic T cells (OT-I) were CFSE-labeled and
injected into mice bearing B16-OVA tumors, followed by i.t. treatment with STING
agonist. The frequency of OT-I T cells in tumor-draining lymph node (dLN) and spleens
was increased in mice treated with c-di-GMP (Fig. 14A). Additionally, these OT-I T
cells divided more (Fig. 14A). However, when similar experiments were performed to
analyze OT-I T cells responses to STING agonists in WT mice treated with IL-15 Ab,
the extent of OT-I proliferation was similar (Fig. 14B) suggesting IL-15 was not critical
for STING-enhanced proliferation of OT-I T cells. This was surprising considering our
previous studies showed STING-mediated bystander proliferation of memory CD8 T
cells was IL-15 dependent (200). Nonetheless, we found that i.t. treatment with STING
agonists increased the percentage of Ki67+ CD8 T cells in the dLN and the spleen but
not in the tumor where frequency of Ki-67+ cells was already high (Fig. 14C). STING
agonists also increased Ki67+ NK cells in the spleen, while STING agonist had only a
minor effect on Ki67+ CD4 T cells in spleen, but not in dLN, and tumor (Fig. 14C).
Furthermore, the increase in the frequency of Ki-67+ among CD8 T cells was
abrogated with treatment with neutralizing IL-15 Ab (Fig. 14C). Ki-67 expression by NK
cells with IL-15 Ab treatment is difficult to analyze as this antibody treatment leads to
the disappearance of NK cells (Fig. 14D) (372).
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Figure 14. STING activation in the TME promotes proliferation of CD8 T cells in
peripheral secondary lymphoid organs. A) Flow cytometry analysis of CFSE dilution
in tumor-specific T cells. WT mice bearing B16-OVA tumors were injected with 0.5x106
CFSE-labelled OT-I cells on day 7 post-implantation and received one i.t. treatment
with c-di-GMP (25g) once tumors became palpable. Three days post-treatment, the
mice were sacrificed and spleen and draining lymph nodes were analyzed by flow
cytometry. B) Flow cytometry analysis of CFSE dilution in OT-I T cells in Spleen and
tumor-draining LNs (dLN) of WT mice bearing B16-OVA tumors. CFSE-labelled OT-I
cells (0.5x106 cells) were injected on day 7 post-implantation and received one i.t.
treatment with c-di-GMP (25g) once tumors became palpable. IL-15 Ab (50g) was
delivered i.p. one day prior to and on the same day as treatment with c-di-GMP. Three
days post-treatment, the mice were sacrificed and spleen and draining lymph nodes
were analyzed by flow cytometry. Frequency of OT-I (CD45.1+) among CD8 T cells
was determined. C) B16-OVA tumors were implanted into WT mice and treated with cdi-GMP on day 12 post-implantation. IL-15 Ab (50g) was delivered i.p. one day prior
to and on the same day as treatment with c-di-GMP. dLN, spleens, and tumors were
isolated three days later and Ki-67 staining by CD8 T cells, CD4 T cells and NK cells
was measured by flow cytometry. D) Representative flow cytometry plots of NK1.1 and
CD4 staining in spleens and B16 tumors treated with IL-15 Ab or IgG (i.p.). Error bars
indicate SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, with One-way ANOVA.
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The effects of i.t. STING agonist treatment on CD8 T cell effector functions were
also investigated. Similar to Ki-67 expression, IFN- and Granzyme B expression by
CD8 T cells were already high in untreated tumors and treatment with c-di-GMP did not
further increase this (Fig. 15 A-C). However, i.t. c-di-GMP led to an increase in IFN expression by CD8 T cells in the spleen that was abrogated by blocking IL-15 (Fig.
15B). A similar effect on IFN- expression by CD8 T cells was observed in dLN but
was not statistically significant (Fig. 15B). Altogether, STING activation in the TME
leads to increased proliferation of CD8 T cells and NK cells and an increased frequency
of IFN-+ CD8 T cells in secondary lymphoid tissues in an IL-15 dependent manner.
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Figure 15. IL-15 produced in response to local STING agonist treatment in
the TME induces IFN- production in CD8 T cells in the periphery. B16-OVA
tumors were implanted into WT mice and treated with 25g of c-di-GMP on day 12
post-implantation. IL-15 Ab (50g) was delivered i.p. one day prior to and on the same
day as treatment with c-di-GMP. dLN, spleens, and tumors were isolated three days
later and Ki-67 staining by CD8 T cells, CD4 T cells and NK cells was measured by
flow cytometry. A) Representative IFN- staining by CD8 T cells from B16 tumors. B)
Graphs show average frequency of IFN- + cells among CD8 T cells isolated from B16
tumors, dLN, and spleens. C) Frequency of Granzyme B+ CD8 T cells from B16
tumors. Error bars indicate SEM, **p<0.01, with One-way ANOVA.
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We next asked whether IL-15 expression induced by STING stimulation was
important for STING-mediated anti-tumor responses. WT and IL-15R-/- mice bearing
palpable B16 tumors were treated i.t. with STING agonist and tumor growth was
measured over time. In the absence of STING stimulation, tumor growth progressed
faster in IL-15R-/- mice than in WT mice providing evidence that IL-15 expression
impacts baseline anti-tumor responses (Fig. 16A & C). While STING agonist induced
potent anti-tumor immunity and tumor regression in WT mice, it failed to induce tumor
regression in IL-15R-/- mice (Fig. 16B). These results indicate that IL-15 is a critical
mediator driving STING-induced tumor regression. A similar dependence on IL-15 was
also observed with STING agonist treatment of MCA-205 tumors in WT and IL-15R-/mice (Fig. 16C). Since IL-15R-/- mice have inherent deficiencies in NK cells and CD8
T cells (389), we used an IL-15 neutralizing Ab to block IL-15 in tumor-bearing WT mice
treated with i.t. STING agonists (Fig. 16B). In the presence of IL-15 neutralizing Ab,
STING-mediated tumor regression was impaired therefore recapitulating the results
observed in IL-15R-/- mice.
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Figure 16. STING activation in the TME promotes tumor regression via IL-15
dependent mechanisms. A) B16-OVA tumor growth in WT and IL-15R-/- mice
treated with i.t. injections of c-di-GMP (25g) or PBS on days 7, 10, and 13 postimplantation (indicated by arrows). Left side panel- grouped tumor growth results. Right
side panels- Spider plot indicating individual tumor growth. n=4-5 mice per group. B)
Tumor growth of B16-OVA tumors in WT mice treated systemically with neutralizing IL15 Ab or PBS (7 days post tumor implantation) followed by three i.t. treatments with cdi-GMP (25g). Tumor growth was significantly different between groups at days 9-15
and days 20-21, p<0.05. C) WT and IL-15R-/- mice bearing MCA-205 tumors on the
right flank received three i.t. injections of STING agonist, c-di-GMP (25g) on days 8,
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11, and 14 post-implantation. (n=4-5 per group). Error bars represent SEM, *p<0.05,
**p<0.01, with Student’s T-test.
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Since we observed IL-15 reporter expression increased upon treatment with
STING agonist, we asked whether the expression of IL-15 by CD11c+ cells was
important for STING-mediated tumor regression. To this end, B16 tumors were
implanted into both CD11c-Cre Tg X IL-15Rfl/fl mice followed by intratumoral
treatment with c-di-GMP or PBS. The ability of STING agonist treatment to induce
regression of tumors was not impaired in CD11c-Cre Tg X IL-15Rfl/fl mice (Fig. 17A
& B) suggesting the tumor regression was not dependent on upregulation of IL-15 by
CD11c+ cells in response to STING stimulation. Additionally, tumor growth was not
increased in untreated CD11c-Cre Tg X IL-15Rfl/fl mice (Fig. 17C).
Since STING agonists have been shown to induce potent systemic anti-tumor
responses resulting in regression of distant tumors (186, 189), we investigated whether
this abscopal effect of STING agonist against a secondary tumor required the
cooperation of IL-15 (Fig. 17D). We also examined whether tumor regression could
also be induced by other STING agonists, such as 2’3’c-GAMP that represents a type
of STING agonist produced by mammalian cells. We found intratumoral 2’3’c-GAMP
induced tumor regression similar to c-di-GMP in an IL-15-dependent manner (Fig.
17D). Furthermore, the STING-mediated tumor regression of a secondary tumor was
also dependent on IL-15. These results show the important role of the IL-15 produced
in the TME in endogenous and STING-agonist induced anti-tumor immunity.
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Figure 17. IL-15 is essential for STING-mediated regression of distant secondary
tumors. A, B) Growth of B16-OVA tumors in CD11c-Cre Tg X IL-15Rfl/fl and WT mice
treated with i.t. injections of c-di-GMP (25g) or PBS on days 7, 10, and 13 postimplantation (indicated by arrows). WT mice were treated alongside the CD11c-Cre Tg
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X IL-15Rfl/fl mice to confirm the effectiveness of c-di-GMP treatment. (n=4-5 per
group). Error bars represent SEM, *p<0.05, ***p<0.001. C) In a separate experiment,
tumor growth of B16-OVA cells was compared in CD11c-Cre Tg X IL-15Rfl/fl and IL15Rfl/fl mice (n= 5-7 mice/group). D) WT and IL-15R-/- mice bearing B16-OVA
tumors on the right flank were implanted with a secondary B16-OVA tumor on the left
flank 72 hours later. The primary tumors were treated with three i.t. injections of 2’3’-cGAMP (15g) or PBS on days 7, 10, and 13. Right panels show tumor growth of
primary tumors while left panels show tumor growth of secondary tumors. n=5 per
group, error bars represent SEM, *p<0.05, **p<0.01, ****p<0.0001 with Student’s Ttest.
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3.3 Summary
IL-15 is a cytokine that is constitutively expressed in multiple tissues for
homeostatic maintenance of several subsets of CD8 T cells and NK cells. Moreover, IL15 can be upregulated when innate immune cells are stimulated and during
inflammation, where it can stimulate cytolytic lymphocyte responses (200, 389). Recent
findings indicate that IL-15 is also produced in human tumors and its absence is
correlated with worst patient outcomes and decreased T cell proliferation in tumors
(346). These findings hinted at the possibility that IL-15 can act as a pro-inflammatory
mediator in the TME. Thus, in this chapter I demonstrated that IL-15 expression is
common in different tumor types, its expression is regulated in the TME, in part due to
IFN-I and upregulation of IL-15 by other inflammatory signals can enhance local and
systemic anti-tumor immune responses.
In this study, the specific cell types that produce IL-15 in the TME using IL-15
GFP reporter mice and conditional knockout mouse models were identified. IL-15
expressing cells in tumors are limited to mainly tumor cells and three myeloid cell
populations including a monocyte-like subset (CD11b+Ly6ChiLy6G-), a granulocytic
subset (CD11b+Ly6G+), and a macrophage-like subset. Although these reporter
systems provide some insight into IL-15 mRNA and protein levels produced in tumors,
they have some limitations that are important to consider. Using these reporter systems
we cannot distinguish between cell surface IL-15/IL-15R complexes and the cleaved
sIL-15 complexes. Importantly, similar to our previous studies we were not able to
detect cell surface IL-15 in tumor myeloid cells (248). However, we were able to
examine the production of sIL-15 complexes using ELISA. We found that sIL-15
complexes in tumors are abundant during early tumor development but decrease as
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tumors become larger. These findings were similar in three different murine tumor
types including melanoma, colon carcinoma and fibrosarcoma. We also discovered that
the high level of sIL-15 complexes found in early tumors is regulated by IFN-I. We also
demonstrated the production of sIL-15 complexes can be increased in more advanced
tumors by direct activation of the STING pathway in tumors. Demonstrating that while
IL-15 expressing cells are present and capable of producing sIL-15 complexes in large
established tumors, they are not receiving potent inflammatory signals to maintain high
production of these IL-15 complexes. Since we were not able to detect transpresented
or cell surface bound IL-15/IL-15R complexes we cannot rule out the possibility that
the regulation and the effects observed in these different tumor types could also be
mediated by transpresented IL-15.
The results described herein also provide evidence that IL-15 produced in tumors
plays important roles in promoting cytotoxic lymphocyte recruitment to tumors. Local
inhibition of IL-15 in tumors led to decreased total numbers of CD8 and NK TILs, without
directly affecting tumor growth. While this was unexpected, as other studies indicate that
presence of cytotoxic TILs is a very important parameter that dictates anti-tumor
responses (82, 390), we interpreted our findings to indicate that the low levels of IL-15
present in tumors, without overt stimulation, are not enough to break the tolerance
established by other immunosuppressive cells and factors in the TME.
While IL-15 levels produced during inflammatory conditions, like viral infections,
can enhance the effector functions and enhance the survival of activated CD8 T cells
we noted no major changes in apoptotic markers or production of effector proteins in
CD8 TILs upon IL-15 neutralization in tumors. One caveat of these experiments is that
although we used smaller doses of IL-15 neutralizing antibody, we cannot disregard the
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possibility that the antibody is leaking into the systemic circulation and some of the
observed effects may be due in part by the systemic loss of IL-15. Nonetheless, while
physiological levels of IL-15 in tumors may not be enough to break tolerance they are
still enough to regulate the number of TILs in tumors.
Conversely, by upregulating IL-15 to higher levels, through activation of the
STING pathway in tumors, we were able to break tolerance and enhance local and
systemic anti-tumor responses. Direct activation of the STING pathway locally or in
response to cell death has shown potent induction of anti-tumor immunity mediated by
CD8 T cells. These responses lead to regression of local and distant tumors (173, 180,
186, 189, 195). Our results demonstrate that STING-mediated primary and secondary
tumor regression depends on IL-15. Specifically, IL-15 was necessary for the observed
STING-induced proliferation and enhanced effector functions of CD8 T cells and NK
cells in secondary lymphoid tissues.
To conclude, I demonstrated that IL-15 is produced early during tumor
development as sIL-15 complexes by cells in the TME, including stromal and tumor
cells. As tumors continue to develop the levels of sIL-15 complexes decrease, likely
due to increases in the tumor to stroma ratio and the immunosuppressive nature of
more established tumors. However, stimulation of IL-15 expressing cells in tumors, with
inflammatory mediators, can upregulate the production of sIL-15 complexes regardless
of tumor size. Notably, the IL-15 produced in response to local inflammatory signals is
critical for mediating systemic anti-tumor responses and tumor regression. Overall,
these findings shed light into previously unknown roles for IL-15 as part of the
inflammatory environment of tumors that potentiates anti-tumor immunity.

110

CHAPTER 4: EFFECT OF INTRATUMORAL IL-15 AGONISTS IN POORLY T-CELL
INFILTRATED TUMORS
4.1 Introduction
Systemic therapy with recombinant IL-15 as a single agent has been difficult to
use in clinical settings due to its poor half-life and its need for continuous infusion to
maintain therapeutic levels of the cytokine in circulation. Thus, as discussed in Chapter
1, it became necessary to create agonists of the physiological version of the cytokine,
which mimic its native conformation bound to IL-15R. While significant success in
preclinical models has been achieved using systemic approaches with these IL-15
agonists and currently several agonists are being evaluated for safety in clinical trials
(391) there are still considerable limitations to their use, including potential off-target
adverse effects and toxicities.
On the other hand, recent preclinical and clinical studies using localized
therapies delivered directly to tumors have shown that intratumoral delivery of immune
stimulating agents is effective at inducing sustained regression of local and distant
secondary tumors (392). The strategies used in these studies include a variety of
agents that aim to use the tumor itself as a type of vaccine to generate specific local
and systemic activation of immune cells. Some of the currently studied agents include a
variety of oncolytic viruses, immune cell receptor stimulators including TLR agonists,
and STING agonists, other chemical agents and direct delivery of DCs into lesions.
For example, studies using intratumoral oncolytic viruses, which can infect and
kill cancer cells, have shown positive clinical outcomes in several types of cancers
including melanomas and liver cancers (393-396). These viruses were genetically
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modified to express the immunostimulatory cytokine granulocyte-macrophage colony
stimulating factor (GM-CSF). In melanoma patients, intratumoral delivery of
Talimogene laherparepvec (T-VEC), a herpes-simplex 1 virus (HSV-1) that expresses
GM-CSF, led to increased durable response rate and increased overall survival, over
GM-CSF alone and in patients with metastatic disease (394, 395).
Another class of intratumoral therapeutic agents that has shown positive clinical
outcomes are small molecule immune modulators including TLR and STING agonists.
In particular preliminary results of a phase I/II clinical trial revealed that intratumoral
administration NKTR-262, a TLR7/8 agonist, in patients with advanced and metastatic
solid tumors, led to a disease control rate of 45% out of a total of 11 patients (397,
398). Our group also showed that intratumoral delivery of poly I:C led to tumor control
in a mouse model of non-muscle invasive bladder carcinoma (399). Furthermore,
intratumoral delivery of cyclic dinucleotides that directly activate the STING pathway
have shown potent local and abscopal effects in mouse models of melanomas and
head and neck cancers (186, 189, 400). Currently a synthetic STING agonist, ADUS100, is being tested in a phase I clinical trial for patients with advanced/metastatic
solid tumors and lymphomas (192).
Intratumoral immunotherapy delivery is particularly attractive to use with drugs
that have dose-limiting toxicities as they allow high levels of available compound to
remain in the tumor environment without the risk of systemic distribution (392). These
strategies are also being used as neoadjuvant therapies for solid tumors with the idea
that they can induce local regression of tumors that might otherwise be very difficult to
resect or treat by conventional therapies (401). There are many ongoing clinical trials
that are using intratumoral therapies in combination with conventional therapies such
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as radiotherapy, chemotherapy and surgical resection (401). Moreover, combination
studies using intratumoral therapies including oncolytic viruses and small molecule
immune modulators and checkpoint inhibitors are currently under way (191, 192, 398,
402-410). Importantly, the majority of the trials that are using intratumoral agents have
been conducted in patients with advanced disease and the main focus has been to test
safety rather than efficacy of the treatments, thus further studies must be performed
once the adequate dosing limits have been established (392, 401, 411).
Based on the results from the studies using other immunostimulatory agents,
and the possible systemic off-target effects using systemic IL-15 therapies, I sought to
deliver IL-15 agonists directly into poorly T-cell infiltrated tumors to assess their effects
on anti-tumor immunity. In this chapter I will demonstrate that local delivery of IL-15
agonists alone can enhance anti-tumor responses and slow tumor growth. Moreover, it
can increase the number of TILs in poorly immune infiltrated tumors and when used in
combination with systemic checkpoint inhibitors can act synergistically to induce tumor
regression and enhance survival.
4.2 Results
4.2.1 Intratumor delivery of recombinant sIL-15/IL-15R-Fc complexes (rsIL-15c)
increases the immune cell infiltrate in melanoma tumors and enhances anti-tumor
responses
Systemic delivery of recombinant soluble IL-15/IL-15R-Fc complexes (rsIL-15c)
induces anti-tumor responses in a variety of tumor models (295-297). Interestingly, the
anti-tumor immune responses induced by systemic rsIL-15c were specifically mediated
by tumor-resident CD8 T cells (295), thus we sought to investigate if local delivery of
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rsIL-15c could promote CD8 T cell responses and induce changes in tumor growth. To
this extent mice bearing palpable B16-OVA tumors were treated with rsIL-15c directly
into tumors and tumor growth and mouse survival were measured (Fig. 18A).
Intratumoral treatment with three doses of rsIL-15c led to slower tumor growth of B16
tumors when compared with control treated mice (Fig. 18B). However, treatment with
rsIL-15c did not induce tumor regression or significantly increase mouse survival (Fig.
18C). Although tumor regression was not observed with treatment, the slower rate of
tumor growth in rslL-15c treated tumors suggested that even at significantly smaller
doses, localized treatment with rsIL-15c could enhance anti-tumor responses.
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Figure 18. Intratumoral delivery of rsIL-15c decreases growth of melanoma
tumors. A) WT mice bearing s.c. B16-OVA tumors were treated with i.t. rsIL-15c or
PBS on days 8, 11 and 14 post implantation and tumor growth and mice survival were
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measured. B) Growth curves for tumors treated with rsIL-15c (red) or PBS (black). Left
panel- grouped tumor growth results. Right side panels- Spider plot indicating individual
tumor growth. C) Kaplan-Meier analysis showing survival of mice from B. n=5, per
group. Error bars indicate SEM, *p<0.05 with Student’s T-test.
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Based in the slower tumor growth observed with intratumoral rsIL-15c treatment
we investigated if the localized delivery of rsIL-15c was enough to increase the amount
of immune infiltrate in tumors. In a similar setup as our tumor growth experiment,
palpable B16-OVA tumors were treated with three doses of rsIL-15c i.t. and tumors
were harvested for flow cytometry analysis (Fig. 19A). We found that tumors treated
with rsIL-15c had increased numbers of infiltrating CD45+ immune cells and CD3+ T
cells (Fig. 19B). Moreover, treated tumors had statistically significant increases in the
numbers of CD4, CD8 and NK TILs (Fig. 19C). The increases in total TIL numbers in
rsIL-15c treated tumors are consistent with others’ findings that increased IL-15 levels
can promote the infiltration of CD8 T cells and other lymphocytes into the inflamed
tissues (265, 266, 412). Moreover, the frequency of CD8 TILs among all T cells in
tumors was significantly increased (Fig. 19D). Consistently, the ratio of CD4:CD8 T
cells was significantly decreased in tumors treated with rsIL-15c (Fig. 19E), suggesting
that treatment preferentially increased the number of CD8 TILs. Taken together these
findings indicate that local increases in IL-15 in tumors can increase the immune cell
infiltrate and potentially convert a non-T cell inflamed tumor into a T-cell inflamed
tumor.

117

Figure 19. Direct delivery of rsIL-15c into tumors increases tumor
infiltrating immune cells. A) WT mice bearing s.c. B16-OVA tumors were treated with
i.t. rsIL-15c on days 8, 11 and 14 after implantation. One day after last treatment
tumors were resected and analyzed by flow cytometry. B) Total number of CD45+ and
CD3+ cells in tumors after i.t. treatment with rsIL-15c or PBS. C) Total number of CD4,
CD8 and NK TILs in tumor treated as in A. D) Frequencies of CD4 and CD8 T cells
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among total CD3+ TILs in tumors treated as in A. E) Ratio of CD4 to CD8 TILs in
tumors treated as in A. n=5, per group. Bars represent SEM, *p<0.05, **p<0.01, with
Student’s T-test.
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4.2.2 Delivery of polymer-conjugated IL-15R agonist NKTR-255 directly into tumors
slows tumor growth and increases immune infiltrate in melanoma tumors
Several versions of IL-15/IL-15R agonists have been developed and were
discussed in Chapter 1. Another novel IL-15R (IL-2/IL-15Rc) agonist, NKTR-255,
was developed by Nektar Therapeutics and is currently being pursued as an immunooncology drug in pre-clinical and clinical studies. NKTR-255 is a polymer-conjugated
human IL-15 protein that has increased in vivo half-life when compared to recombinant
IL-15 and has shown promise in the treatment of solid and hematological malignancies
(308, 310). Previous pre-clinical studies in mice and non-human primates have used
NKTR-255 as a systemic therapy for several cancer types and found that it
preferentially stimulates CD8 T cells and NK cell proliferation and responses (309).
Moreover, in lung-metastasis models of colon cancer they found that treatment with
NKTR-255 led to 85% decrease of metastasis in an NK cell-dependent manner (309).
Currently, NKTR-255 is being evaluated in a phase I dose-escalation clinical trial for
refractory multiple myeloma and non-Hodgkin lymphoma as a monotherapy and in
combination with targeted antibodies including anti-CD38 monoclonal antibody
daratumumab and rituximab, an anti-CD20 monoclonal antibody (310).
Since most pre-clinical studies to date using NKTR-255 have used a systemic
therapeutic approach, we asked if local delivery of NKTR-255 into tumors could
promote anti-tumor responses by tumor infiltrating immune cells. To investigate this, we
treated mice bearing palpable melanoma tumors with intratumoral injections of NKTR255 and measured tumor growth and analyzed tumor infiltrating immune cells by flow
cytometry (Fig. 20A). Intratumoral treatment with NKTR-255 significantly slowed the
tumor growth of melanoma tumors when compared to untreated control tumors (Fig.
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20B). TIL numbers were increased including CD4, CD8 and NK cells (Fig. 20C),
although results did not achieve statistical significance. Interestingly, the number of
CD11b+ tumor infiltrating myeloid cells was also increased with treatment, and among
CD11b+ cells only an increase in Ly6Chi cells was observed, while no increase in
Ly6G+ cells was detected (Fig. 20C). These results suggest increased IL-15 levels in
the TME, achieved by local treatment with NKTR-255, is enough to increase the levels
of tumor-infiltrating immune cells including myeloid and lymphoid cells to slow tumor
growth progression in poorly infiltrated melanoma tumors.
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Figure 20. Localized delivery of NKTR-255 into tumors decreases tumor growth
and augments the immune cells found in melanoma tumors. A) WT mice bearing
B16-OVA tumors were treated with 60ng of NKTR-255 i.t. or no treatment on days 5, 7,
9, 11, 14, 16 and 18 post-tumor implantation. On day 19 tumors were harvested for
flow cytometry analysis. B) Growth curves for tumors treated with NKTR-255 (red) or
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PBS (black). Left panel- grouped tumor growth results. Right panels- Spider plots
indicating individual tumor growth. C) Numbers of CD8 T cells, CD4 T cells, NK cells
and CD11b+ cells in B16-OVA tumors treated as in A, normalized to tumor weight. D)
Numbers of Ly6Chi and Ly6G+ positive myeloid cells in B16-OVA tumors treated as in
A, normalized to tumor weight. n=3-5 mice/group. Error bars represent SEM, *p<0.05,
**p<0.01, with Student’s T-test.
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4.2.3 Combination therapy with intratumoral IL-15/IL-15R agonists and immune
checkpoint inhibitors delays tumor growth and enhances mice survival
The new era for immunotherapeutic drugs began with the discovery of immune
checkpoints, receptors on the cell surface of lymphocytes, that serve as natural
regulatory mechanisms to ensure that immune responses are controlled and do not
cause autoimmunity. While the CTLA-4 and PD-1 proteins were discovered in 1987
and 1992, respectively, their roles as immune checkpoints were not appreciated at the
time (413, 414). In 1995 Jim Allison showed that engagement of CTLA-4, on the
surface of T cells, with B7 on other cells negatively regulated T-cell activation and the
use of an anti-CTLA-4 antibody enhanced T cell proliferation (415). Consequently,
Allison’s group also showed that systemic delivery of an anti-CTLA-4 antibody could
induce tumor regression and protection against a secondary tumor challenge (416).
Similar findings in multiple tumors models including melanomas and prostate cancers,
using anti-CTLA-4 monotherapy and combination therapy with other immunotherapy
strategies (417-424) provided strong preclinical evidence to move forward with testing
anti-CTLA-4 checkpoint blockade in human and non-human primates (425-430).
Positive clinical outcomes from clinical trials in patients with advanced melanoma led to
FDA approval of ipilimumab, a monoclonal antibody against CTLA-4, as an
immunotherapy drug for patients with inoperable and metastatic melanoma in 2011.
Since then tens of combination approaches using several immune checkpoint inhibitors
and therapies including targeted antibodies, radiotherapy, chemotherapy and other
immune based therapies have been tested and many approved for a variety of solid
tumors (356).
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As our understanding of the challenges faced by cytotoxic lymphocytes in the
TME becomes more thorough, it has become quite evident that combination therapy to
combat different mechanisms of immunosuppression in the TME will be necessary to
achieve long lasting and curative responses in most malignancies. Consequently, we
focused on investigating if combination therapy with immune checkpoint inhibitors and
localized IL-15 agonists could act in synergy to enhance anti-tumor immunity in a
poorly immunogenic melanoma tumor model. Hence, mice bearing palpable B16-OVA
tumors received systemic treatment with anti-CTLA-4 Ab in combination with
intratumoral rsIL-15c (Fig. 21A). Monotherapy with anti-CTLA-4 Ab did not control
tumor growth (Fig. 21B, blue lines), similar to previous findings by Allison’s group,
where this treatment was not capable of overcoming the tolerance mechanisms in
these poorly infiltrated and poorly immunogenic tumors (422). Nonetheless,
combination treatment with anti-CTLA-4Ab and rsIL-15c induced significant tumor
growth control of melanoma tumors (Fig. 21B, red lines). Moreover, the effects of
combination therapy extended to significantly improving mouse survival (Fig. 21C).
Taken together, these results suggest that local delivery of IL-15 agonists can act
synergistically with systemic immune checkpoint blockade to induce better tumor
growth control and increase survival in mice bearing poorly immunogenic tumors.
Future experiments should be performed to look specifically at the amount and
activation status of immune cells of tumors treated with combination therapy of antiCTLA-4 and rsIL-15c, because it is possible that by treating with rsIL-15c directly into
tumors we have increased the infiltration of cytotoxic lymphocytes, such as CD8 T
cells, into tumors, thus turning these poorly-infiltrated tumors into T-cell-inflamed
tumors.
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Figure 21. Combination therapy with systemic anti-CTLA-4 and intratumor rsIL15c controls tumor growth and increases survival in mice with melanoma
tumors. A) Mice bearing B16-OVA tumors were treated with anti-CTLA-4 Ab or
polyclonal hamster IgG i.p. on days 5,8,11,14 and 18 post-tumor implantation. Tumors
were treated with i.t rsIL-15c complexes or PBS on days 8, 11 and 14 post126

implantation. Tumor growth and mouse survival were measured. B) Tumor growth
curves for mice treated as in A. Left panel- Grouped tumor growth results. Right
panels- Spider-plots showing individual tumor growth. C) Kaplan-Meier analysis
showing survival of mice from B. n=5 mice/group. Error bars represent SEM, *p<0.05,
**p<0.01, with Student’s T-test or Log-rank Test.
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4.3 Summary
The immunosuppressive nature of the TME and the physical and biochemical
barriers cytotoxic lymphocytes encounter to infiltrate, survive and execute their antitumor functions present big challenges for immune based therapeutics. Clinical
evidence points to a positive relationship between the amount of infiltrating cytotoxic
lymphocytes found in patient tumors and their responses to immune checkpoint
blockade agents (360, 431, 432). Tumor classification based on T cell infiltration can
stratify tumors in two main types: T-cell inflamed and non-T cell inflamed tumors. On
one end of the spectrum, non-T cell inflamed tumors can have low levels or completely
lack the presence of T cells and these “cold” tumors are less likely to respond to
therapy with immune checkpoint inhibitors. On the other hand, there are “hot” tumors or
T cell inflamed tumors that have abundant tumor infiltrating T cells and patients with
these types of tumors have better clinical outcomes using immune checkpoint
inhibitors. As the number of TILs correlates with better responses to immunotherapy
agents, an important strategy to improve the efficacy and applicability of immune
checkpoint blockade therapy and other immune based therapies is to find avenues to
increase the infiltration and total numbers of lymphocytes in tumors.
In chapter 3 of this dissertation I demonstrated that expression of IL-15 in the
TME can regulate the number of CD8 and NK TILs found in tumors likely due to its
ability to promote infiltration of these lymphocytes into tumors. Based on those findings
I investigated if local upregulation of IL-15 in tumors, by intratumoral delivery of IL-15
agonists, could positively affect anti-tumor responses by CD8 T cells and other TILs. As
systemic treatment with IL-15 and its agonists could enhance anti-tumor responses in
multiple solid tumor models, I used an intratumoral approach to deliver IL-15 agonists
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to tumors. I also studied the effects of combination therapy with intratumoral IL-15
agonists and immune checkpoint inhibitors.
Delivery of rsIL-15c into tumors increased the amount of CD4, CD8 and NK TILs
found in tumors and induced tumor growth control on melanoma tumors. Moreover,
intratumoral delivery of a polymer-conjugated human IL-15 protein, NKTR-255, that
shows improved bioavailability and half-life over recombinant IL-15, also induced
significant tumor growth control and increased the immune cell infiltrates in melanoma
tumors. These findings suggest that local increases in IL-15 levels in tumors are
sufficient to improve the amount of TILs found in poorly infiltrated melanoma tumors,
and that localized strategies to deliver IL-15 agonists or other agents that upregulate IL15 production into tumors should be further explored for their potential benefits.
. Typically, preclinical studies using checkpoint inhibitors in poorly immunogenic
tumors, like B16 melanomas, rely on the concurrent administration of cancer cell
vaccines that express GM-CSF or Flt3-ligand to enhance the efficacy of checkpoint
inhibitors (422, 433-436). These combination approaches using multiple checkpoint
inhibitors and cancer vaccines are thought to increase the anti-tumor T cell immunity by
enhancing T cell infiltration, increasing the inflammatory state of the tumors by
upregulating cytokines like IFN-, and enhancing the activation of CD8 T cells in tumors
(434). Taking a similar approach to enhance T cell immunity, I showed that combination
treatment with anti-CTLA-4 and local rsIL-15c induced significant tumor growth control
when compared to either monotherapy. Furthermore, the combination approach
significantly improved survival of mice bearing B16 tumors. The results from these
experiments support my hypothesis that increasing levels of IL-15 locally in the TME
can potentially convert poorly infiltrated tumors into T cell inflamed tumors that can
129

benefit from systemic immune checkpoint inhibitor therapy or other combinations of
immune based therapeutics (Fig. 22).

Figure 22. Intratumoral IL-15 agonists synergize with immune checkpoint
blockade to enhance therapeutic responses in poorly immunogenic tumors.
Poorly immunogenic and tumors that have low numbers of tumor infiltrating T cells are
also known as cold tumors. In our model, cold tumors produce low levels of IL-15 and
using intratumoral delivery of IL-15 agonists the immune cell infiltrate and T cell
infiltrate in these cold tumors increases, turning these tumors into hot tumors.
Combination therapy with immune checkpoint inhibitors, specifically anti-CTLA-4
therapy, and IL-15 agonists led to better tumor growth control and increased survival in
mice.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
The limited long-term benefits of cancer immune-based therapies, including
immune checkpoint blockade, to a small subset of patients and tumor types has shed
light into the importance of determining which attributes of tumors and their
microenvironment make them more permissive to mount potent anti-tumor immunity.
Immune cell infiltration, particularly of tumor-infiltrating T cells, has been associated
with positive clinical outcomes in a variety of cancers, including melanoma and
colorectal tumors (82-85). Specifically, the density, location in the tumor, and cytotoxic
activity of CD8 T cells are associated with better clinical outcomes (82, 437).
Consequently, understanding what factors in the TME promote better T cell infiltration
can lead to improved clinical responses to current immunotherapies and to develop
novel immunotherapy strategies that provide more clinical benefits to a broader
population of patients and tumor types.
IL-15 is a pleiotropic cytokine that is important for the survival and maintenance
of specific subsets of CD8 T cells and NK cells and has also been shown to enhance
anti-tumor immunity as an immunotherapy agent. In human tumors, IL-15 expression
correlated with better clinical outcomes and increased T cell proliferation in colorectal
tumors (346). In this dissertation I set out to investigate the hypothesis that IL-15
produced in the TME is an important promoter of cytotoxic lymphocytes anti-tumor
responses by stimulating optimal numbers in the TME and enhancing their cytotoxic
and metabolic functions. As IL-15 in the TME is important for regulating numbers of
TILs, these findings suggest that IL-15 produced in tumors is an important inflammatory
cytokine produced by tumor cells and stromal cells that can influence how adaptive
lymphocytes access and infiltrate tumor masses and survive in this environment.
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Moreover, IL-15 produced in response to intratumoral innate immune cell agonists
enhances both local and systemic anti-tumor immune responses. These findings
suggest that IL-15 production by innate immune cells in the TME can be boosted to
stimulate responses by other lymphocytes against tumor cells.
My findings that sIL-15 complexes are produced at high levels early on during
tumor development followed by infiltration of CD8 TILs suggest that upregulation of IL15 in the tumor could be an important inflammatory reaction likely promoting priming,
activation and recruitment of cytotoxic lymphocytes to the tumor site. Moreover, the
variety of cellular sources of sIL-15 complexes in the TME, including tumor and stromal
cells, show that upon recognition of tumor-derived antigens or products of cellular
death spontaneous anti-tumor immune responses are generated that upregulate IL-15
production. Importantly, IFN-I generation, as a result of activation of the STING
pathway, is necessary for spontaneous priming of tumor-specific CD8 T cells (173) and
I showed that IFN-I signaling regulated production of sIL-15 complexes and TIL
numbers early during tumor development. Thus, IFN-I regulate TIL numbers in tumors
in part due to their upregulation of IL-15 in the TME. Furthermore, these findings
suggest that any other agents that could promote IFN-I production could also stimulate
and positively regulate IL-15 production and could be studied in the context of tumor
immunology.
In this dissertation I also showed that many myeloid cell types and even nonhematopoietic cells in the TME can express IL-15 in the TME. It was interesting that
while I looked at several tumor types, the composition of myeloid cells that express IL15 in the TME in these different tumor types was very similar. Regardless of the tumor
type analyzed, the majority of the cells that expressed IL-15 in the TME were CD11b+
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Ly6ChiLy6G- cells, and due to their expression levels of CCR2 and the fact that they
express IL-15, these cells likely represent classical inflammatory monocytes rather than
monocytic MDSCs. However, more in-depth functional studies would have to be
performed to ascertain the exact nature of these cells.
Importantly, while I detected low levels of sIL-15 complexes in advanced tumors,
upon delivery of a STING agonist into the tumor the IL-15 producing cells in the TME
responded by upregulating IL-15 expression and sIL-15 complexes production.
Consequently, while IL-15 expression in the TME is negatively regulated as tumors
become more advanced IL-15-producing cells are capable of upregulating IL-15
expression if they receive strong inflammatory signals. These findings could provide
evidence to use other inflammatory mediators to promote IL-15 production in the TME.
Since numerous inflammatory stimuli upregulate IL-15 transcription and production of
sIL-15 complexes (199, 200, 240, 274), I suspect that other inflammatory pathways
could have a similar effect. Thus, currently used innate immune stimulators could
potentially exert their effects in part by increasing IL-15 production. It would be thoughtprovoking to use other agonists of PRRs like TLR agonists such as Poly I:C, that when
used peritumorally induce IFN-I production in poorly immune infiltrated melanoma
tumors (438), to investigate if the anti-tumor effects observed are also mediated by IL15 upregulation.
An important physiological process that affects the cytotoxic functions of CD8
and NK TILs is the competition for nutrients with cancer cells and the challenges they
face to maintain their metabolic fitness in the suppressive TME. Activated CD8 T cells
rely on glucose metabolism and activated NK cells rely on both glycolysis and FAO to
generate the energy sources needed to exert and maintain their effector functions (439133

441). Moreover, mitochondrial content and function is also crucial for the survival and
metabolic function of both memory CD8 T cells and activated NK cells (439-441). In
these studies IL-15 blockade in the TME did not significantly impact the glucose
metabolism of CD8 TILs. Furthermore, I was not able to examine NK cell glucose
metabolism because the NK cell population is dependent on IL-15 for survival, and
depletion of IL-15 from the TME led to complete loss of this population of lymphocytes.
However, I think that further research should be performed to specifically examine if IL15 in the tumor, whether endogenous or delivered as a therapeutic could be inducing
changes in the metabolic state of T cells and NK cells in tumors.
It is important to look at possible effects on metabolism mediated by IL-15
because IL-15 was found to increase mitochondrial biogenesis, promote OXPHOS and
FAO in activated CD8 T cells in vitro (388, 442) and induce the PI3K/AKT/mTOR
pathway in memory CD8 T cells (389). Furthermore, treatment with rsIL-15c led to
accumulation of effector CD8 T cells in mucosal tissues in an mTOR dependent
manner (412). For NK cells, IL-15 activates the PI3K/AKT/mTOR pathway for the
survival, proliferation and IFN- production (443, 444). An experimental approach that
could be used to examine the effect of IL-15 on TIL metabolism is performing
extracellular flux analysis to analyze both glycolytic and FAO engagement and to obtain
information about mitochondrial fitness, including mitochondrial mass and membrane
potential. Moreover, if changes in metabolic activity are observed with IL-15 treatment
or blockade then it would be important to examine the contribution of mTOR to these
metabolic changes by using mTOR inhibitors.
While investigating the specific mechanisms by which basal levels of IL-15 in
tumors regulate TIL numbers, my findings strongly suggest that IL-15 could be
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promoting trafficking and infiltration of TILs into tumors. IL-15 has been shown to play
a direct role in promotion of T cell infiltration into inflamed tissues. In vitro IL-15 can act
as a chemoattractant of T cells and NK cells (267, 268) and in vivo can promote CD8 T
cell infiltration to sites of infection and inflammation (266, 272, 412). Although IL-15 can
induce infiltration of CD8 T cells to inflamed tissues, it remains to be clearly defined
whether IL-15 is critical for their migration and infiltration into the TME. In pilot
experiments, not shown in this dissertation, using naïve and activated antigen-specific
CD8 T cells I tried examining antigen-specific CD8 T cell infiltration into tumors upon IL15 blockade; however, several experimental difficulties with this model led me to
conclude that other approaches should be used to measure the potential role of TMEderived IL-15 on TIL trafficking.
Some suggestions to directly measure the role of TME-derived IL-15 in
promoting TIL infiltration include the use of intravital time-lapse two-photon imaging to
directly observe the trafficking of transferred antigen-specific cytotoxic lymphocytes
expressing recombinant fluorescent proteins. For example, intravital two photon
imaging has been used to visualize GFP expressing OT-I T cells trafficking into OVAexpressing EL4 thymoma tumors in a model of adoptive cell therapy (445). Another
approach would be to directly look at TIL infiltration using immunohistochemistry or
immunofluorescence of tumor samples treated with IL-15 antibody blockade or in
tumors where IL-15 could be conditionally knocked-out using Cre-recombinase
inducible systems. Futhermore, IL-15 has been shown to enhance the expression of
LFA-1 on T cells and NK cells and promotes transendothelial migration of T cells in
mouse models of rheumatoid arthritis (264, 268). Moreover the interaction of LFA-1 on
cytotoxic lymphocytes and its ligand ICAM-1 on the cell surface of tumor cells is
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required for tumor-cell killing by these lymphocytes (446). Thus examining the
expression of this integrin on TILs from IL-15 depleted tumors would serve as another
strategy to investigate if IL-15 directly enhances TIL infiltration into tumors.
IL-15 can also promote migration and infiltration of T cells via other indirect
mechanisms that include the upregulation of chemokines and chemokine receptors in
myeloid cells and cytotoxic lymphocytes, respectively (447). Of interest are the IFN-inducible chemokines CXCL9 and CXCL10 produced by APCs. These chemokines,
produced by Batf3+ DCs are key in mediating infiltration and recruitment of CXCR3+
CD8 T cells into tumors (53, 54, 448-451). Recently, a study using heterodimeric IL-15
as a systemic therapy in MC-38 tumors showed that this IL-15 agonist can upregulate
the expression of chemokines CXCL9 and CXCL10 by myeloid cells in the TME,
including DCs and macrophages, in part due to increased IFN- production by TILs
(452-454). Furthermore, IL-15 can increase the expression of the receptor for these
chemokines, CXCR3, on CD8 T cells (455).
Accordingly, investigating if intratumoral treatment with IL-15 agonists can also
enhance the infiltration of TILs into poorly infiltrated tumors would be an important next
step to further elucidate how IL-15 therapeutics directly or indirectly enhance anti-tumor
immune responses. Several experimental approaches could be used including
measuring the levels of chemokines in the tumor using multiplex or ELISA for specific
chemokines. Furthermore, expression of chemokine receptors on TILs could be
measured using flow cytometry and gene expression profiling techniques could be
used to examine upregulated and downregulated genes. Demonstrating that increased
IL-15 levels in tumors could enhance infiltration of T cells into tumors could provide
strong and direct evidence that IL-15 can potentially convert cold tumors into T-cell
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inflamed tumors. This in turn could lead to better combination strategies with other
immune-based therapies to ensure that more patients with different tumor types can
obtain long term benefits from immunotherapy. As an example, several IL-15 agonists
are already undergoing clinical trials in combination with immune checkpoint blockade
for PD-1 (NCT03520686, (345)), as IL-15 can induce the upregulation of PD-1 and PDL1 on T cells and (340, 344). Therefore, as I showed that the use of IL-15 and its
agonists as intratumoral agents increased the immune infiltrate in tumors and can act
cooperatively when used in combination with checkpoint inhibitors against CTLA-4,
then the next possible step could be to combine intratumoral IL-15 agonists with other
checkpoint inhibitors and possibly with other therapies including adoptive cell therapies.
Based on the findings in this dissertation, I propose the use of intratumoral
treatment strategies to increase the levels of IL-15 in the TME to aid in the conversion of
non-T cell inflamed or cold tumors into T-cell inflamed or hot tumors. While intratumoral
delivery of immune based therapies circumvents the issues faced with systemic delivery
in regard to dose-limiting toxicities, this delivery system has several disadvantages that
must be considered when designing combination therapies. The first obvious
disadvantage would be the difficulty of accessing many types of solid tumors as most
clinical trials performed to date using intratumoral therapies have been conducted in
easily accessible lesions like skin and breast cancers. However, recent developments in
radiologic and diagnostic imaging techniques are now thought to bypass the issue of
accessibility as long as primary lesions or metastatic lesions can be localized using any
of these new imaging and diagnostic modalities (401, 456, 457).
Another practical disadvantage for intratumoral agents includes the possibility of
requiring multiple doses delivered to the tumor site for generation of sustained systemic
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immunity (401). Therefore, developing strategies that deliver these therapeutic agents
into the tumors and maintain them localized to the tumor site, limiting their diffusion to
the systemic circulation, are necessary to reduce the need for repetitive dosing and the
potential to generate systemic toxicities (456). Several approaches have been developed
to deliver immunotherapeutic agents like cytokines, such as IL-2 and IL-15, and immune
checkpoint inhibitors to tumors and ensure slow release of the drug and limit the
dissemination to the circulation. These approaches are based on conjugating these
drugs to nanoparticles, liposomes and biodegradable polymers (456, 458-460). In short,
intratumoral delivery of IL-2 encapsulated in microspheres of gelatin and chondroitin
sulfate had a slower continuous in vivo release for 21 days and induced protective
immunity in mouse models of brain and liver metastasis (458). IL-15 agonists have been
delivered to the peritumoral space using alginate matrices and this led to tumor growth
control of B16 melanoma tumors and infiltration of leukocytes into the tumor (461).
Immune checkpoint blockade antibodies against CTLA-4 have been injected into tumors
in water and oil emulsions leading to slower release of the antibody while maintaining
tumor eradication without autoimmune adverse effects observed with systemic therapy
(460). Lastly, Wang et al developed degradable microneedle patches, which can be
applied to the skin, that release dextran nanoparticles conjugated to anti-PD-1 mAb that
release the drug upon encounter of an acidic environment and this enhanced survival of
mice in a melanoma tumor model (462). Consequently, the use of one or more of these
approaches could be applied when considering the use of IL-15 agonists or other agents
that can upregulate IL-15 in the TME as intratumoral therapies.
One last aspect to consider in the studies performed in this dissertation is the fact
that we only used transplantable subcutaneous mouse tumor models. Subcutaneous
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mouse tumor models provide important advantages including highly reproducible and
rapid growth of tumors and easy tumor growth monitoring by visual inspection and
manual measurements (463). However, since they arise from a clonal population of cells
that have been cultivated, they may lack the heterogeneity observed in naturally
developing tumors and since they are implanted in tissues different from their tissues of
origin they fail to receive the adequate cues that can lead to development of a different
inflammatory tumor microenvironment (464). Nevertheless, these mouse models have
been widely used for the study of cancer immunotherapy drugs, including immune
checkpoint inhibitors, and their results have been validated in clinical trials and thus
continue to serve as important models for immuno-oncology research. A different
approach that could have been taken was using orthotopic tumor models where
syngeneic mouse tumor cells are implanted into the organ or tissues of the same
histologic type as the tumor cells (463). While these orthotopic tumors develop in the
organs or tissues of origin, they still present some disadvantages because they are
derived from cultured cell lines that lack the genetic heterogeneity that is found in human
tumors. Other mouse tumor models that could be used to circumvent the limitations of
transplantable tumor models are genetically engineered mouse models in which tissuespecific overexpression of oncogenes or deletion of tumor suppressor genes can lead to
spontaneous development of tumors. It would be interesting to perform studies using
these different types of mouse tumor models in experiments using local IL-15 therapies
to elucidate how the tumor microenvironment and the development of mutations over
time affect the response to these therapeutics.
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